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G protein-coupled receptors (GPCRs) are known to interact with several other classes of 
integral membrane proteins. However, the extent of these interactions and their role in regulating 
GPCR-mediated transmembrane signaling is not well understood. For example, receptor activity-
modifying proteins (RAMPs), a family of single transmembrane proteins with only three 
members, are ubiquitously expressed and have been shown to interact with several different 
GPCRs.  Most research to date has focused on the ability of RAMPs to modulate the function of 
several GPCRs in the secretin-like GPCR family. GPCR-RAMP interactions were shown to 
affect the ligand binding affinity of two different secretin-like GPCRs, causing the functional 
diversity of the GPCRs to be driven by an interacting protein. Yet, potential direct interactions 
among the three known RAMPs and hundreds of non-olfactory GPCR has never been 
investigated and whether RAMP-GPCR interactions are widespread remains an open question. 
To determine the breadth of GPCR-RAMP interactions, we first investigated the global 
coexpression and coevolution between GPCRs and RAMPs. On the one hand, if many GPCRs 
interact with RAMPs we would except to see statistically significant coexpression and 
coevolution in comparison to random gene pairs. On the other hand, if GPCR-RAMP 
interactions are limited to a small number of genes, then averaged coexpression and coevolution 
would be similar to that expected by chance. To calculate coexpression, we analyzed an RNA-
Seq database of human transcriptomes across 53 different tissues and found that coexpression 
between non-olfactory GPCRs and RAMPs is significantly higher than random gene pairs. We 
also analyzed genomic data from all currently available sequenced organisms to calculate the 
coevolution between non-olfactory GPCRs and RAMPs. We discovered that GPCRs and 
RAMPs have a significant percentage of shared species and significantly correlated phylogenetic 
trees. Our results support the hypothesis that GPCRs interact globally with RAMPs. 
Only a handful of GPCR-RAMP interactions have been reported to date, but our 
coexpression and coevolution analysis suggested that additional GPCRs interact with RAMPs. 
To begin to address the potential for direct interactions among the three known RAMPs and 
hundreds of GPCRs, we developed a highly multiplexed immunoassay using a suspension bead 
array (SBA) assay designed to detect RAMP-GPCR complexes. We engineered three epitope-
tagged RAMPs and 23 epitope-tagged GPCRs, including all members of the secretin-like family 
of GPCRs, as well as eight other GPCRs. We then used 64 antibodies raised against native 
RAMPs and GPCRs, along with four antibodies targeting the epitope tags, to multiplex the SBA 
assay to detect and measure all possible combinations of interaction among the 23 GPCRs and 
three RAMPs from detergent-solubilized lysates. We also used the epitope-tagged constructs to 
verify a collection of antibodies that target native GPCRs and RAMPs. We validated nearly all 
previously reported secretin-like GPCR-RAMP interactions, and also found previously 
unidentified RAMP interactions with additional secretin-like GPCRs, chemokine receptors, and 
orphan receptors. Using in situ proximity ligation assay, we verified a subset of these novel 
GPCR-RAMP interactions in cell membranes. The results of the SBA assay provide a complete
interactome of secretin-like GPCRs with RAMPs. GPCR-RAMP interactions are more common 
than previously appreciated, and the SBA strategy will be useful to search for additional GPCR-
RAMP complexes and other interacting membrane protein pairs in cell lines and tissues. 
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CHAPTER 1. Introduction 
1.1 G protein-coupled receptor (GPCR) structure and signaling 
Cells within organisms have evolved intricate systems to sense and respond to their local 
environments and to communicate intercellularly and intracellularly. Cell signaling occurs over a 
range of distances - within an individual cell, between nearby cells and over long distances in the 
body. Many secreted intercellular signaling molecules, which are key to physiological responses, 
are unable to penetrate through the plasma membrane, and instead mediate effects by binding to 
specific cell surface receptors on target cells. The largest family of these plasma membrane 
receptors are G protein-coupled receptors (GPCRs), termed for their ability to activate 
intracellular heterotrimeric G proteins. The first two GPCRs to be biochemically characterized 
and sequenced were rhodopsin, a light-sensing receptor that binds an 11-cis-retinylidene 
chromophore, and the b2-adrenergic receptor, which mediates the effects of the potent stress 
hormones adrenalin and noradrenaline (1–4). Despite their disparate ligands and physiological 
responses, both receptors were predicted to have a similar topological structure, with seven 
transmembrane spans. The molecular cloning of the b2-adrenergic in 1986 facilitated the cloning 
of several additional GPCRs over the next several years (5–7). Yet the GPCRs cloned prior to 
the release of the human genome sequence represented just a small fraction of the total number 
of GPCRs. By analyzing the human genome, Fredriksson et al. and Takeda et al. identified 
approximately 800 genes that were thought to encode GPCRs (8, 9). The extensive repertoire of 
GPCR genes is mirrored by the diverse array of ligands that activate GPCRs, including but not 
limited to photons, odorants, hormones, histamine and dopamine.  
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GPCRs are the most ubiquitous plasma membrane receptors, expressed in every tissue and 
cell type and regulating nearly all known physiological functions. GPCRs function as signal 
transducers by changing conformation in response to the binding of an extracellular agonist 
ligand. The conformational change of the GPCR opens up a pocket on the intracellular side to 
allow binding and activation of the G protein, thereby transferring information from the 
extracellular to the intracellular side. The G protein is a heterotrimeric protein consisting of a Ga 
subunit in complex with Gbg subunits. The GPCR activates the G protein by catalyzing the 
exchange of GDP for GTP within Ga, allowing the dissociation of the G protein heterotrimer 
into constituent Ga and Gbg components (Figure 1-1). The Ga protein subtypes include Gs, Gi/o,
Gq/11, and G12/13. Depending on the particular G protein subtype and its cellular context, either 
Ga or Gbg, can mediate downstream effector activity through activation or inhibition of 
enzymes or channels.  
Figure 1-1. GPCR signaling through heterotrimeric G proteins. An agonist ligand binds to the 
GPCR causing a conformational change. In response, the heterotrimeric G protein, composed of 
Ga, Gb, and Gg, binds to the GPCR and GDP is exchanged for GTP within the Ga subunit. The 
heterotrimeric G protein then dissociates into Ga and Gbg to activate or inactivate various 
enzymes and channels.   
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Following activation, the receptors must be desensitized to maintain cellular homeostasis 
and prepare to respond to new stimuli. Desensitization of the GPCR is accomplished through 
phosphorylation of Ser/Thr residues on the cytoplasmic C-terminal tail by GPCR kinases 
(GRKs). Phosphorylation of the GPCR mediates b-arrestin recruitment, blocking further G 
protein coupling. b-arrestin then facilitates receptor sequestration or internalization in addition to 
activating noncanonical signaling systems such as mitogen-activated protein kinase pathways 
(10). The internalized receptor is either recycled back to the cell membrane or degraded.  
Historically, GPCR signaling was believed to involve sequential activation of a single type 
of Ga protein class followed by b-arrestin-dependent activation of noncanonical signal 
pathways. Activation was believed to be binary, with a receptor acting somewhat like a 
molecular switch that would adopt either an active or inactive structure. It has now been 
established that GPCR activation and signaling is a much more complex process. There are 
multiple states along the energetic pathway from the inactive to active conformation of a GPCR, 
as well as probably several active state conformations (11). The multi-faceted conformational 
states allow activation of several different downstream signaling pathways. For example, many 
GPCRs couple to and signal through multiple G protein classes in response to an activating 
ligand. Also, GPCR agonists demonstrate signaling bias towards either G protein or b-arrestin 
pathways (12). Signaling bias has also been shown to occur at the level of different G protein 
subclasses, where certain ligands would activate one G protein subclass and other ligands would 
activate another subclass (13).  
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1.2 Classifications of GPCRs 
The GPCR signaling paradigm is fairly limited within the “Tree of Life”, being utilized by 
eukaryotic organisms, with the exception of plants (14). Virally-encoded GPCRs have also been 
described (15). Yeast, one of the simplest eukaryotic organisms, has only two GPCRs (16).  In 
humans, the evolutionary processes of gene duplication and subsequent mutations led to a large 
expansion in the number of GPCR subtypes (17, 18).  While all GPCRs display the canonical 
seven transmembrane structure, they have substantial differences in lengths of the N-terminal 
tails, C-terminal tails, and extracellular loops, as well as various post-translation modifications. 
Based on phylogenetic analysis, human GPCRs are grouped into five primary receptor families – 
rhodopsin, glutamate, adhesion, frizzled/TAS2, and secretin – and are differentiated by structural 
features and molecular composition of ligands (19) (Figure 1-2). The rhodopsin-like GPCR 
family constitutes by far the largest number of GPCRs, with a total of ~700 members, and are 
characterized by relatively short N-terminal tails. Within rhodopsin-like GPCR family, the 
majority of receptor types respond to odorant molecules and are termed olfactory GPCRs. Non-
olfactory, rhodopsin-like GPCRs respond to a chemically diverse set of ligands including 
amines, purines, lipids, peptides, and large glycoproteins. Glutamate-like receptors bind to small 
molecule ligands via a distinctive N-terminal Venus-flytrap domain. The secretin-like family is 
composed of 15 GPCRs that share a conserved N-terminal hormone-docking/binding domain, 
which plays a pivotal role in the binding of large peptide, hormone ligands. The adhesion-like 
family of GPCRs is characterized by a very long N-terminal tail (200-2800 amino acids) with 
multiple O- and S-glycosylation sites, as well as epidermal growth factor and GPCR proteolytic 
domains that are important for their ability to facility cellular adhesion. Finally, the frizzled 
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receptors respond to secreted glycoproteins named WNTs, which are instrumental in embryonic 
development. The term WNT is a portmanteau coined from Wingless-related integration site 
(20). 
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Figure 1-2. Phylogenetic relationship between GPCRs in the human genome. There are 
approximately 800 GPCRs that can be categorized into five major families based on sequence 
similarity: adhesion, secretin, glutamate, frizzled/TAS2, and rhodopsin. Numbers in parentheses 
indicate the number of GPCRs in the family. The phylogenetic tree was adapted from (19, 21)
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1.3 GPCRs in drug discovery 
GPCRs are tractable pharmaceutical targets because of their ubiquitous expression, 
“druggable” ligand-binding pockets, and access to the extracellular milieu. Highlighting the 
clinical importance of GPCRs, 457 approved drugs (~36% of all approved drugs) have been 
developed that target 134 specific GPCRs (22). However, although drugs that target GPCRs are 
over-represented in the pharmacopeia of FDA-approved drugs, only about one-third of non-
olfactory GPCRs have been targeted to date, and 401 GPCR-targeted drugs, or ~70%, act 
through the 35 aminergic receptor. The aminergic receptors include adrenoreceptors, muscarinic 
acetylcholine receptors and receptors for serotonin, dopamine and histamine. Approximately 140 
of the non-olfactory GPCRs remain “orphans,” whose endogenous physiological agonist is 
unknown (23). Thus, there remain many potential opportunities for the development of more 
GPCR-targeted pharmaceuticals. Current clinical trials have begun to address novel GPCR 
targets. Amongst the 321 drugs in clinical trials that target GPCRs, about 20% target 66 GPCRs 
that have yet to be therapeutically exploited (Figure 1-3). Rapidly increasing numbers of crystal 
structures, new agent types, such as monoclonal antibodies, and new targets will greatly assist 
future GPCR-targeted drug development (24, 25).  
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Figure 1-3. GPCRs targeted by drugs that are approved and in clinical trials. Of the non-
olfactory GPCRs, 108 have drugs approved (green), 66 have agents in clinical trial (red), and 224 
have not been targeted (middle panel). The 108 established GPCR drug targets (left panel) are 
primarily aminergic receptors (blue). The 66 currently untargeted GPCRs with agents in clinical 
trial (right panel) are primarily peptide and protein receptors (purple). Figure adapted from (22)  
As additional GPCRs are investigated as therapeutic targets, the number of disease 
indications for potential GPCR-targeting drugs has also expanded. Some disease indications 
targeted by approved GPCR-targeting drugs address dysfunctions of the central nervous system 
(CNS) disorders highlighting the critical role of GPCRs in neurotransmission. These drugs target 
a variety of GPCRs, including 5-hydroxytryptamine (serotonin), dopamine, opioid, and 
cannabinoid receptors for the treatment of mood disorders, pain, epilepsy, and psychosis (26). 
New CNS disorder indications with GPCR-targeted drugs in clinical trials address additional 
CNS dysfunctions, including multiple sclerosis, Alzheimer's disease, and Huntington’s disease. 
GPCRs also play a pivotal role in energy homeostasis, and the development of medications for 
type 2 diabetes and obesity has increasingly focused on GPCRs, with approved drugs targeting 
glucagon-like receptor 1 (GLP1R) (27). In addition, more GPCRs have been implicated in cancer 
development and the establishment of the tumor microenvironment. Aberrant expression of 
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GPCRs is found in a variety of cancers, and both inactivating and activating mutations in GPCRs 
drive cancer formation and progression (28, 29). For example, a mutation in cysteinyl 
leukotriene receptor 2 causes the receptor to be constitutively active and is responsible for 5% of 
uveal melanoma cases (30). As more research has revealed the roles of different GPCRs in 
cancer, oncological therapeutics has become increasingly focused on GPCRs (28). 
1.4 GPCR interactions with transmembrane proteins 
Traditionally, GPCRs were believed to exist and function as monomers. It is now 
appreciated that many GPCRs form homo- and hetero- oligomers. The potential to target 
oligomeric forms of GPCRs remains an untapped area for GPCR drug discovery. The GPCR 
interaction network database, GPCR-HetNet [http://www.gpcr-hetnet.com] indicates a total of 
537 interactions between GPCRs, encompassing 183 GPCRs (31).  The functional role of these 
interactions depends on the particular GPCRs involved. Members of the glutamate GPCR family 
function and exist as stable homodimers. For other GPCRs, the role of oligomerization is less 
clear since several rhodopsin-like GPCRs function as monomers (32–35). However, receptor 
oligomerization affects ligand binding affinity for some GPCRs (36). Some GPCR oligomers are 
disease specific and provide attractive targets for L-DOPA-induced dyskinesia, morphine 
tolerance, and alcohol-induced liver fibrosis (37, 38). In addition, GPCR oligomers provide the 
opportunity for development of more selective drugs with less chance of side effects.  
While the number of known GPCR-GPCR interactions continues to expand, less 
appreciated is the potential for GPCRs to interact with other transmembrane proteins. The 
number of transmembrane proteins known to interact with GPCRs is currently limited and 
10 
includes receptor transport proteins (RTPs), receptor expression-enhancing protein (REEP), 
melanocortin receptor accessory proteins (MRAP), M10 major histocompatibility protein 
(MHC), and receptor activity-modifying proteins (RAMPs). Each of these single transmembrane 
proteins has been shown to chaperone particular GPCRs to the cell surface (39). Despite the 
limited knowledge about transmembrane proteins that interact with GPCRs, a GPCR-RAMP 
complex is the only GPCR oligomers targeted by FDA-approved drugs (40). More information 
on GPCR-membrane protein interactions will contribute to further GPCR-targeted drug 
discovery and development.    
1.5 Discovery of receptor-activity modifying proteins (RAMPs) 
The family of RAMP proteins were initially discovered in the search for the receptor for 
calcitonin gene-related peptide (CGRP). CALCRL was recognized to be a likely candidate, due 
to its homology to the calcitonin receptor (CALCR). However, expression of CALCRL alone 
caused only a subset of tested cell lines to be responsive to CGRP, suggesting that another 
protein expressed in the sensitive cell lines was required to form a functional receptor for CGRP. 
Using an expression cloning approach, McLatchie et al. discovered that RAMP1 was the 
additional component required for CALCRL functionality and that CALCRL required to 
RAMP1 to be transported to the cell membrane (41). Database searches for homologous proteins 
revealed two additional proteins belonging to the RAMP family, RAMP2 and RAMP3, with 
31% homology. Surprisingly, coexpression of CALCRL with RAMP2 or RAMP3 leads to a 
receptor responsive to a different peptide hormone, adrenomedullin (41–43).  
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The change in ligand binding affinity as a consequence of RAMP association was also 
observed with another receptor closely related to CALCRL, calcitonin receptor (CALCR). 
CALCR binds with a high affinity to calcitonin in the absence of RAMP association, but 
becomes an amylin receptor in the presence of any of the three RAMPs (44, 45). In contrast to 
CALCRL, CALCR does not require RAMP expression for localization to the cell membrane. 
These initial studies on RAMP interactions with the calcitonin subfamily of GPCRs created a 
paradigm shift in the GPCR field by revealing that the functional diversity of GPCRs can be 
driven by interacting proteins. 
 
1.6 Functional domains and structural features of RAMPs 
 
The three members of the RAMP family have a similar secondary structure, although 
they share only ~30% sequence identity. Each RAMP has a long extracellular N-terminal tail of 
~90-100 amino acids, which contributes to determining ligand specificity (46). The N-terminus 
of RAMP2 contains one N-linked glycosylation site, and RAMP3 has four N-linked 
glycosylation sites. Although both RAMP2 and RAMP3 are linked to adrenomedullin 
pharmacology, the glycosylation sites do not determine the ligand binding specificity (43). The 
C-terminal tails of RAMPs are relatively short, being only 9 amino acids long. Within the C-
terminal tail of each RAMP is an endoplasmic reticulum (ER) retention signal that prevents 
RAMP translocation to the cell surface in the absence of an interacting GPCR. The C-terminus 
of RAMP3 also contains a type 1 PDZ recognition site that contributes to the modulation of 
receptor trafficking.  
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Structural studies of RAMP interaction with CALCRL indicate that the molecular 
mechanism by which RAMPs influence ligand binding to CALCRL are subtle. Studies with 
chimeric, extracellular domain (ECD) proteins show that both RAMP1 and RAMP2 have ECDs 
with a three-helix bundle fold and similar interaction with CALCRL. Because RAMPs make 
only minimal contacts to the agonist, the molecular mechanism by which RAMPs affect ligand 
binding to CALCRL is mostly through allosteric shaping of CALCRL (46–48). Although the 
ECD-ECD contacts between RAMPs and CALCRL are important in ligand binding, RAMPs 
also interact with GPCRs through the transmembrane domain to form stable complexes. 
Recently, a cryogenic electron microscopy structure of a complex including RAMP1, CALCRL, 
CGRP, and a Gs protein heterotrimer defined the interaction of the transmembrane domains and 
confirmed findings from previous crystal structures of the ECDs (49). RAMP1 forms extensive 
contacts with CALCRL, causing 23% of the RAMP1 surface to be buried. The TM domain of 
RAMP1 nestles into an interface between TM helices 3, 4 and 5 of CALCRL, and the ECD of 
RAMP1 interacts with the extracellular loop 2 (ECL2) of CALCRL. As seen in the crystal 
structures, there are minimal contacts between RAMP1 and the agonist CGRP (Figure 1-4).   
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Figure 1-4. Structure of the RAMP1, CALCRL, and CGRP complex. Salmon, RAMP1; cyan, 




1.7 Consequences of RAMP interaction with GPCRs 
While CALCRL and CALCR have been the most studied RAMP-interacting GPCRs, 
several additional secretin-like receptors, as well as a rhodopsin-like and glutamate-like receptor 
also interact with RAMPs (Table 1-1). Due to their endoplasmic reticulum retention signal, 
RAMPs are generally poorly expressed on the cell membrane in the absence of an interacting 
GPCR. Thus, additional GPCR-RAMP interactions were determined by assessing RAMP cell 
surface localization upon coexpression of the putative interacting GPCR. These studies 
established that GPCRs demonstrate selectivity for certain RAMPs and that RAMP interaction 
was not universal for secretin-like receptors. However, the consequences of many of these 
interactions have not been investigated. Notably, the handful of studies addressing the function 
of RAMP association with GPCRs have failed to reveal the distinctive switch in ligand affinity 
seen with CALCRL and CALCR. Instead, the glucagon receptor (GCGR) may lose its ability to 
bind GLP-1 with RAMP2 coexpression, but studies have shown conflicting results (50, 51). 
RAMPs instead have effects on GPCRs beyond ligand binding affinity. Investigations on the 
consequence of RAMP interaction with GPCRs have demonstrated that RAMPs alter GPCR 
trafficking and G-protein signaling in a receptor-, agonist-, and pathway-dependent manner.  
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Table 1-1. GPCRs reported to interact with RAMPs. Listed are the abbreviation of the GPCRs, 
GPCR family, RAMP interaction(s), and references. 
GPCR Abbreviation GPCR family RAMP interaction 
Calcitonin receptor-like receptor CALCRL Secretin RAMP1, 2 and 3 (41) 
Calcitonin receptor CALCR Secretin RAMP1, 2 and 3 (44, 45) 
Corticotropin-releasing hormone 
receptor 1 CRHR1 Secretin RAMP2 (52, 53) 
Glucagon receptor GCGR Secretin RAMP2 (50, 51, 54) 
Growth hormone-releasing 
hormone GHRHR Secretin None (54) 
Glucagon-like receptor 1 GLP1R Secretin None (50, 54, 55) 
Glucagon-like receptor 2 GLP2R Secretin None (54) 
Parathyroid hormone receptor 1 PTH1R Secretin RAMP2 (54) 
Parathyroid hormone receptor 2 PTH2R Secretin RAMP3 (54) 
Secretin receptor SCTR Secretin RAMP3 (56) 
VIP and PACAP receptor 1 VIPR1 Secretin RAMP1, 2 and 3 (54) 
VIP and PACAP receptor 2 VIPR2 Secretin RAMP1, 2, and 3 (55) 
G protein-coupled estrogen 
receptor 1 
GPER1/ 
GPR30 Rhodopsin RAMP3 (9) 
Calcium-sensing receptor CaSR Glutamate RAMP1 and 3 (57–59) 
One of the first functions ascribed to RAMPs was their chaperoning role with CALCRL 
(41).  In the absence of RAMPs, CALCRL is poorly localized to the cell membrane. RAMPs 
also act as a chaperone for several additional GPCRs – CRHR1, SCTR, GPER1 and CaSR (9, 
53, 55–57). But RAMPs may also have the opposite effect on GPCR trafficking. GCGR 
demonstrates reduced cell surface expression upon coexpression of RAMP2 when assayed in 
CHO cells, but not in HEK293S cells (50, 51).  
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RAMPs also modulate and participate in receptor internalization and post-internalization 
trafficking. For CALCRL, RAMPs and CALCRL remain complexed during the internalization 
process. The PDZ binding domain on RAMP3 can interact with N-ethylmaleimide-sensitive 
factor (60) or Na+/H+ exchange regulatory factor-1 to promote CALCRL recycling or inhibit 
receptor internalization, respectively (61). Agonist-induced b-arrestin recruitment to GCGR is 
completely inhibited upon RAMP2 coexpression, although the effects of on receptor 
internalization have not been explored (51).  
The effects of RAMPs on GPCR downstream signaling pathways are pleiotropic, and 
thus far, no clear patterns have emerged. However, it is important to note that unlike CALCRL, 
other RAMP-interacting GPCRs traffic to the cell surface in the absence of RAMP coexpression. 
Thus, both RAMP-free and RAMP-associated GPCRs are present on the cell surface, potentially 
masking pharmacological effects. The effects of RAMP association on receptor pharmacology 
has only been investigated for CALCR, CaSR, CRHR1, GCGR, and VIPR1. Depending on the 
receptor, RAMPs can either augment or inhibit GPCR signaling through different downstream 
signaling pathways (50, 51, 55, 58, 62). However, outside of the chaperoning function of 
RAMPs for some interacting GPCRs, it remains unclear how RAMPs modulate G protein 
signaling. Structural studies do not demonstrate direct contacts between RAMP1 and G protein, 
suggesting that changes in signaling is likely accomplished through allosteric modulation of the 
receptor structure (49).  
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1.8 Role of RAMPs in physiology 
To date, physiological studies have focused on the interaction between RAMPs and just a 
subset of interacting GPCRs, largely CALCRL. RAMP knockout mice show expected 
abnormalities in blood pressure regulation and cardioprotection that are linked to actions of the 
two peptides that signal through CALCRL-RAMP complexes, CGRP and adrenomedullin. 
However, the different RAMP transgenic mouse models demonstrate distinctive phenotypes. It is 
important to note that other GPCRs may also be involved in the phenotypes of RAMP transgenic 
mice.  
CGRP signals through the CALCRL-RAMP1 complex and has clinical importance in 
migraines. Ramp1-/- mice are viable but show dysfunction in the vascular system as well as an 
alteration in inflammatory responses (63–65). In mice with neural overexpression of RAMP1, 
increased sensitivity to CGRP causes increased neurogenic inflammation (66). Excess CGRP 
induces migraines by causing vasodilation, and thus, monoclonal antibodies (mAbs) have been 
developed to block the interaction between CGRP and CALCRL-RAMP1. These antagonizing 
mAbs are the first RAMP-targeted therapeutics to be FDA-approved (67, 68).  
 Although both RAMP2 and RAMP3 complex with CALCRL to form a receptor for 
adrenomedullin, knockout mice of RAMP2 and RAMP3 have revealed distinct roles of these two 
RAMP isoforms. Genetic loss of RAMP2 causes embryonic lethality due to defects in vascular 
development and cardiac mitochondrial dysregulation (69). Consistent with the role of RAMP2 
in vasculature, endothelial restoration of RAMP2 expression rescues Ramp2-/- lethality, but mice 
still exhibit cardiomyopathy (70, 71). Haplosufficient RAMP2 mice survive to birth but 
demonstrate increased vascular permeability (72, 73). In contrast to RAMP2, RAMP3-/- mice 
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have no major abnormalities, but exhibit higher blood pressure, and reduced lymphatic vessel 
function (65, 72, 74, 75). The phenotypes described above are recapitulated by genetic loss of 
Calcrl, Adrenomedullin, or Cgrp (76).  
More research is needed to uncover the physiological role of RAMP interactions with 
other GPCRs. Only a handful of studies have begun to show that the physiological role of 
RAMPs is not limited to the modulation of CALCRL. Yet several of the phenotypes that RAMP 
knockout mice display are distinct from Calcrl, Adrenomedullin, or Cgrp knockout mice. With 
regards to the CALCR-RAMP1 complex, neuronal overexpression of RAMP1 in mice leads to 
sensitization of amylin, leading to increased energy expenditure (66). Alteration of RAMP2 
expression also leads to changes in expression of GPCRs other than CALCRL and CALCR, 
including Gcgr and Pth1r. For PTH1R, reduced expression causes an attenuated response to 
parathyroid hormone, resulting in improper placental development (70, 77). Reduction in 
RAMP2 expression also attenuates the ability of CRF1 to induce stimulation of adrenal 
corticotropin hormone, a vital hormone in the stress response (55). RAMP3 acts as a chaperone 
and serves as an essential regulator of GPER30 function. Genetic loss of RAMP3 eliminated the 
cardioprotective effects of GPR30 activation in chronic hypertension and cardiac hypertrophy 
mouse model (9). These and other GPCR-RAMP complexes beyond CALCRL are potential 
therapeutic targets for the treatment of heart failure, infertility, and anxiety.  
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1.9 Identification of previously unknown GPCR-RAMP interactions 
The breadth of GPCR-RAMP interactions remains unclear and warrants further 
investigation. Several lines of evidence suggest that more GPCR-RAMP interactions remain to 
be discovered. RAMPs are ubiquitously expressed throughout human tissues, indicating a broad 
role in human physiology (41). RAMP transgenic mice have unexpected phenotypes, such as 
infertility, that cannot be linked to the well-established RAMP-CALCRL complexes (77, 78).  
Only 15, or ~4%, of all non-olfactory GPCRs have been studied for interactions with 
GPCRs. The vast majority of the GPCRs investigated for RAMP interaction have focused on the 
secretin-like GPCRs. Yet, both a rhodopsin-like and a glutamate-like GPCR interact with 
RAMPs (9, 57). This opens up the possibility that more GPCRs outside the secretin-like family 
are also modulated by RAMP interaction. Compellingly, CXCR7/ACKR3, a rhodopsin-like 
GPCR, binds to adrenomedullin, the agonist for the CALCRL-RAMP2 and CALCRL-RAMP3 
complexes (79).  
Even the previously identified secretin-like GPCRs that have been determined to interact 
with RAMPs require further study. Except for a few, these GPCR-RAMP interactions have not 
been confirmed by direct methods or are reported in only one publication. In some cases, the 
literature provides conflicting information as to whether a GPCR interacts with RAMPs or not. 
To date, a complete secretin-like GPCR-RAMP interactome has not been described.  
 Thus, I was interested in developing methods to identify previously undescribed GPCR-
RAMP interactions. With nearly 340 non-olfactory GPCRs, pairwise investigation of GPCR-
RAMP interactions would be prohibitive. Thus, I took two approaches to address GPCR-RAMP 
interactions in a high-throughput and scalable fashion. First, I implemented computational 
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approaches to investigate the possibility of global interactions between RAMPs and GPCRs. If 
RAMPs interact with many GPCRs, as opposed to the few that are reported in the literature, we 
expected to observe significant coevolution and coexpression. I then developed a multiplexed 
immunoassay to screen for direct interaction between RAMPs and all secretin-like GPCRs, as 
well as several other GPCRs. This method, which utilized the suspension bead array and 
Luminex technologies, is highly scalable and can be used to screen for all GPCR-RAMP 
interactions as well as GPCR-membrane protein interactions more generally. 
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CHAPTER 2. Materials and Methods 
2.1 Bioinformatics analysis 
2.1.1 Percent of shared species 
Orthologs of human RAMPs and GPCRs were identified using the OMA database (80). 
To calculate percent shared species among gene pairs, we first constructed lists of species for 
each gene, in which one can find orthologs. Percent of shared species for a pair of genes a and b 
(PSS(a,b)) was calculated by the intersection of species lists for gene a (Sa) and gene b (Sb), 
divided by their union, multiplied by 100:  
𝑃𝑆𝑆(𝑎, 𝑏) =
𝑆𝑎 ∩ 𝑆𝑏
𝑆𝑎 ∪ 𝑆𝑏 × 100 
Intersection and union are operations from set theory.  
2.1.2 Phylogenetic comparison 
For species that contained both a GPCR and a RAMP ortholog we first aligned 
orthologous sequences using the BLOSUM50 scoring matrix, which is based on local alignments
(98).  Then a matrix of pairwise sequence distance, or the evolutionary rate of change between 
two gene pairs, was calculated using the Jukes-Cantor algorithm to build the phylogenetic trees  
(99) (MatLab, Bioinformatics Toolbox, seqlinkage).  We compared phylogenetic trees using two 
methods. First, we compared trees by calculating the correlation between two genes based on 
pair-wise distances among species. The second method we used is an established phylogeny 
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comparison algorithm (81). This algorithm is based on pruning tree branches and comparing the 
resulting species partitions. The full algorithm can be found in the above citation. Briefly, given 
a pair of phylogenetic trees, the algorithm arbitrarily chooses one tree, goes through each of the 
edges (i.e., branches) and prunes the tree in this spot. This pruning produces two subtrees which 
determine a specific partition of the leaf nodes (this is the first partition for the first tree). 
Similarly, all the possible partitions produced by edge pruning of the second tree are generated 
and compared with the first partition of the first tree. A score representing the similarity of each 
partition pairs is calculated. The same procedure is performed for all the other edges of the first 
tree. Next, the optimal match between branch pruning-derived partitions of the two trees is 
attained with the Munkres algorithm (also known as the Hungarian algorithm). Lastly, a global 
similarity score based on the optimal branches match is calculated. 
2.1.3  ‘Tree of life' normalization 
When comparing phylogenetic patterns of two genes across species of varying 
classifications, the primary determinant of the comparison is the global phylogenetic distance 
between the species. To reduce the global phylogenetic distance effect and directly compare the 
phylogenetic patterns of specific gene pairs, it is necessary to normalize the trees by the general 
‘tree of life’ (82). We compared phylogenetic patterns between genes using matrices of amino 
acid sequence distance and normalized by the 18S rRNA matrix. Normalizing distance matrices 
by the 18S rRNA matrix introduces a higher correlation among the compared genes than the 
non-normalized matrices. In addition, the normalization procedure reduced the global 
phylogenetic distance by mixing the inter- and intra-species clusters. Hence, normalization to the 
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‘tree of life’ corrects for the inter-species basal distances and enables the specific protein pair to 
govern the correlation strength. 
2.1.4 Coexpression analysis 
RNA-seq data from 53 tissues provided by 544 donors, with a total of 8555 samples, 
were downloaded from gtexportal.org (GTEx_Analysis_v6p_RNA-seq_RNA-
SeQCv1.1.8_gene_rpkm.gct.gz). Downloaded data was provided as reads per kilobase per 
million mapped reads (RPKM). Only samples passing quality control were included in the 
dataset. Read counts, and RPKM values were produced with RNA-SeQC; importantly, reads 
were mapped to a single gene (see gtexportal.org documentation for more information). For 
transcripts per kilobase million (TPM) normalization, the RPKM of each gene was divided by 
the total RPKM for the sample and multiplied by 106. For rank normalization, each gene in each 
sample was ranked in descending order (highest RPKM having the highest numeric rank). For 
quantile normalization, gene expression across an individual sample was fit to the averaged 
distribution observed across samples. Before implementing the Spearman correlation analysis, 
the median normalized expression (RPKM, TPM, rank, or quantile) per tissue was calculated to 
account for differences in the number of samples per tissue type. Spearman correlation 
coefficient was calculated for each RAMP-non-olfactory GPCR pair as well as ligand-receptor, 
receptor subunit and random gene pairs. For coexpression analysis by GPCR cluster, GPCR 
clusters were assigned as per Fredriksson et al. (19).  
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2.2 DNA constructs 
2.2.1 RAMP constructs 
Epitope-tagged human RAMP DNA constructs were encoded in a pcDNA3.1(+) 
mammalian expression vector. The human RAMP1, RAMP2, and RAMP3 cDNAs encoded an 
N-terminal FLAG tag (DYKDDDDK) following the signal peptide (amino acids 1-26, 1-42 and 
1-27 for RAMP1, RAMP2 and RAMP3 respectively) and a C-terminal OLLAS tag 
(SGFANELGPRLMGK). The RAMP DNA constructs were codon-optimized for expression in 
human cell lines. 
2.2.2 Secretin-like and ADGRF5 GPCR constructs 
Epitope-tagged human secretin-like GPCR DNA constructs were encoded in a 
pcDNA3.1(+) mammalian expression vector. The human secretin-like GPCR and ADGRF5 
cDNAs encoded a 5-hydroxytryptamine receptor 3a receptor (5-HT3a) signal sequence 
(MRLCIPQVLLALFLSMLTGPGEG) in place of the native signal sequence, as determined by 
SignalP 4.1 (Table 2-1) (83). Also, an N-terminal hemagglutinin (HA) tag (YPYDVPDYA) 
followed the 5-HT3a signal sequence, and the C-terminus encoded a 1D4 tag (TETSQVAPA). 
The secretin-like GPCR and ADGRF5 DNA constructs were codon-optimized for expression in 
human cell lines.   
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Table 2-1. Signal sequence of each secretin-like GPCR. Signal sequences were determined by 
SignalP4.1 (83).  

















2.2.3 Chemokine and orphan GPCR constructs 
Epitope-tagged human GPCR DNA constructs were encoded in a pcDNA3.1(+) 
mammalian expression vector. Expression constructs of human GPR182, GPR4, and CXCR3 
cDNAs encoded an N-terminal HA tag (cDNA.org). The human CCR5, CCR7, CXCR4, and 
ACKR3/CXCR7 cDNA encoded a C-terminal 1D4 epitope tag. 
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2.2.4 Immunoblot validation of RAMP and GPCR constructs 
Solubilized lysates were combined with NuPAGE loading buffer with 100 mM DTT and 
resolved by SDS-PAGE using NuPAGE 4-12% Bis-Tris gel (Thermo Fisher). Proteins were 
transferred to an Immobilon PVDF membrane-Fl (Sigma-Aldrich) using a semi-dry transfer 
apparatus. The membranes were then blocked in Odyssey blocking buffer (LI-COR) for one hour 
at room temperature and incubated overnight at 4ºC with antibodies (Abs) diluted in blocking 
buffer with the addition of 0.2% Tween-20. The dilutions used for each Ab were 1:5000 for anti-
1D4 mouse monoclonal, 1:2000 for anti-OLLAS rat monoclonal, 1:1000 for anti-FLAG rabbit 
polyclonal (Sigma-Aldrich), and 1:1000 anti-HA rabbit polyclonal (Cell Signaling). Membranes 
were washed 3 x 10 minutes in wash buffer (PBS + 0.1% Tween) and then incubated with goat 
anti-mouse IR 680 or goat anti-rabbit 800 CW (LI-COR) diluted to 1:10,000 in Odyssey 
blocking buffer supplemented with 0.2% Tween-20 for one hour at room temperature. Follow 
washing 3 x 10 min in wash buffer, protein bands were visualized using an Odyssey SA (LI-
COR). 
2.2.5 Cell surface expression validation of RAMP and GPCR constructs 
Transfected HEK293 Freestyle cells (Thermo Fisher), approximately 1,000,000 in 0.5 
mL media, were harvested and washed once in Hank’s balanced salt solution (Thermo Fisher) 
with 20 mM HEPES (HBSS-H) + 0.5% bovine serum albumin (BSA) (Roche). PE anti-FLAG 
(BioLegend) diluted to 1:2000 in 100 µL HBSS-H + 0.5% BSA was added to the cells, and Ab 
binding occurred for 45 min at 4ºC. Following Ab incubation, cells were washed 2 times with 1 
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mL of HBSS-H + 0.5% BSA. The surface expression of each RAMP was quantified by flow 
cytometry using the Accuri C6 flow cytometer (BD Biosciences). 
2.2.6 Adenylyl cyclase activity validation of RAMP and GPCR constructs 
Production of cAMP production in response to adrenomedullin was monitored in 
HEK293T cells coexpressing epitope-tagged CALCRL and a RAMP2 construct (either RAMP2, 
FLAG-RAMP2, or FLAG-RAMP2-OLLAS). In addition, the reporter plasmid RLuc3-EPAC-
GFP10 was also coexpressed and acts as a BRET2 biosensor for cAMP levels as previously 
described (84). For each well of a 96-well plate, HEK293T cells (100,000 in 0.1 mL) were 
transiently transfected with 12 ng of RLuc3-EPAC-GFP10, a BRET2 cAMP sensor, with or 
without cotransfection of 100 ng of CALCRL and/or 100 ng of RAMP2. Total DNA was 
brought up to 212 ng with pcDNA3.1(+) when needed. Cells were transfected using 
Lipofectamine 2000 (Thermo Fisher) and plated at 100 µL/well in a 96-well plate previously 
coated with 0.01% (w/v) poly-D-Lysine (Sigma-Aldrich). Twenty-four hours post-transfection, 
media was replaced by BRET Buffer (phosphate buffer saline containing 0.5mM MgCl2 and 
0.1% BSA). Coelenterazine 400A (Biotum) was added to a final concentration of 5 µM, 
followed by a 10 min incubation at room temperature. Cells were then stimulated with increasing 
concentration of adrenomedullin (AnaSpec) for 15 min at room temperature or with 5 μM of 
forskolin (Sigma-Aldrich) to induce the maximal cAMP production response. Luminescence and 
fluorescence readings were collected using the Synergy NEO2 plate reader and Gen5 software 
(BioTek). BRET2 readings between RLuc3 and GFP10 were collected by sequential integration 
of the signals detected in the 365- to 435- nm (RLuc3) and 505- to 525- nm (GFP10) windows. 
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BRET2 ratios were calculated as previously described and are expressed as a percentage of 
forskolin-stimulated response (84). Dose-response curves were derived with GraphPad Prism. 
2.3 Suspension bead array (SBA) experiments 
2.3.1 Cell culture and transfection 
HEK293F cells were cultured in serum-free Freestyle 293 Expression media using 125 
mL disposable culture flasks (Thermo Fisher). Cells were shaken constantly at 125 rpm at 37°C 
with 5% CO2. The day prior to transfection, the HEK293 freestyle cells were diluted to 600,000 
cells/mL and allowed to grow overnight. The next day 3 mL of cells were transferred to one well 
of a 6-well plate. Each well of cells was transfected with 0.5 µg indicated RAMP plasmid DNA, 
and/or 0.5 µg indicated GPCR plasmid DNA with 3 µL Freestyle MAX Reagent (Thermo 
Fisher). Total transfected plasmid DNA was kept constant at 3 µg by adding empty vector 
pcDNA3.1(+). 
2.3.2 Lysate preparation 
HEK293 Freestyle cells were solubilized with n-Dodecyl-b-D-maltoside (DM) detergent 
(Anatrace) to form micelles around membrane proteins and maintain GPCR and RAMP structure 
and complex formation. Twenty-four hours post-transfection, transfected HEK293F cells were 
harvested and washed once with cold phosphate-buffered saline (PBS). Cells were then 
incubated in solubilization buffer (50 mM HEPES, 1 mM EDTA, 150 mM NaCl, 5 mM MgCl2, 
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pH 7.4) with 1% (w/v) DM and cOmplete protease inhibitor (Roche) for two hours at 4°C with 
nutation. Following solubilization, lysates were clarified by centrifugation at 22k x g for 20 min 
at 4ºC. Lysates were then transferred to a microcentrifuge tube, and total protein content was 
determined by Protein DC assay according to the manufacturer's specifications (Bio-Rad). 
2.3.3 Generation of the SBA 
The SBA was produced by covalently coupling Abs to MagPlex Beads (Luminex Corp), 
which are magnetic, bar-coded beads where each bar-code is defined by a unique combination of 
infrared and near red dyes. Each Ab was coupled to a unique bead identity, as previously 
described (85). In brief, 1.6 µg of each Ab was diluted in MES buffer (100 mM 2-(N-
morpholino)ethanesulfonic acid pH 5.0) (Sigma-Aldrich) to a final volume of 100 µL. The 
carboxylated surface of the magnetic beads was then activated with N-hydroxysuccinimide 
(Pierce) and 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (Proteochem). After twenty 
minutes incubation with the activation solution, the diluted Abs were added to the beads, and 
coupling occurred for two hours at room temperature. Beads were then washed and stored in 
blocking reagent for ELISA (BRE) (Roche), a protein-containing blocking buffer, with the 
addition of ProClin300 (Sigma-Aldrich). The coupling efficiency for each Ab was determined by 
incubating the beads with PE-conjugated anti-rabbit IgG or PE-conjugated anti-mouse IgG 
(Jackson ImmunoResearch). 
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2.3.4 SBA assay procedure 
Lysates were incubated with an aliquot of the SBA. Protein associated with each bead in 
the SBA was detected with a phycoerythrin (PE)-conjugated Ab. Lysates were diluted to 50 
µg/mL in solubilization buffer containing 0.1% (w/v) DM, to a total volume of 25 µL in a half-
volume, 96-well plate (Grenier). An equal amount of 2x SBA assay buffer (PBS containing 1% 
(w/v) polyvinyl alcohol (PVA) (Sigma-Aldrich), 1.6% (w/v) polyvinylpyrrolidone (PVP) 
(Sigma-Aldrich), 0.2% (w/v) casein (Sigma-Aldrich), and 20% rabbit-IgG (Bethyl)) was added 
to the diluted lysates. Aliquots of the SBA, containing 50-100 beads for each bead ID, were 
added to the lysates in 50 µL of 1x SBA assay buffer (PBS containing 0.5% PVA (w/v), 0.8% 
PVP (w/v), 0.1% (w/v) casein, and 10% rabbit IgG). The lysates and beads were incubated 
overnight at 4°C. Then the beads were washed five times with 100 µL PBS containing 0.05% 
Tween-20 (PBST) using a EL406 washer (BioTek). Beads were then incubated with 50 µL of 
PE-conjugated detection Abs diluted in BRE containing 0.1% DM, 0.1% Tween-20, and 10% 
rabbit IgG. The final dilutions used for the detection Abs were 1:1000 for PE-conjugated anti-
FLAG (BioLegend) and PE-conjugated anti-1D4, 1:500 for PE-conjugated anti-OLLAS, and 
1:200 for PE-conjugated anti-HA (BioLegend). PE conjugation to 1D4 and OLLAS Abs was 
performed according to manufacturer’s directions (Abcam). Following incubation at 4°C for one 
hour, the beads were washed three times with 100 µL PBST. After the final wash, 100 µL of 
PBST was added to the beads, and the fluorescence associated with each bead was measured in a 
FlexMap3D instrument (Luminex Corp). 
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2.3.5 SBA data analysis 
 
For GPCR-RAMP interactions determined through capture and detection of epitope tags, 
an ordinary one-way ANOVA, with Dunnett’s multiple comparisons test, was used to compare 
MFI from the lysates cotransfected with an epitope-tagged RAMP and epitope-tagged GPCR to 
MFI from the negative control, mock transfected cells (Prism 7, Graphad). MFIs from at least 
three experiments performed in duplicate were used in the statistical analysis (Fig 4-5). We then 
calculated a combined statistical measure. The p-values for the GPCR-RAMP complexes 
determined by each capture-detection Ab pair were then converted to 4 for p £ 0.0001, a 3 for p 
£ 0.001, a 2 for p £ 0.01, a 1 for p £ 0.05, or a 0 for p > .05. For each GPCR-RAMP complex the 
converted p-values were added up and divided by either eight (for dual-tagged GPCRs) or four 
(for single-tagged GPCRs).  
A Kruskal-Wallis ANOVA was used to compare the MFI from lysates transfected with 
RAMP1, RAMP2 and RAMP3 for RAMP Ab validation, with at least 200 experiments 
performed in duplicate (R package) (Fig 4-6).  Statistical significance of GPCR Ab validation 
was determined using a single-tail Z-test comparing the signal from all Abs for each lysate with 
at least three experiments performed in duplicate for each lysate (Excel, Microsoft) (Figure 4-7 
and Figure 4-8).  Statistical significance of GPCR-RAMP complex formation captured by GPCR 
Abs was also determined using a single-tail Z-test comparing the signal from all Abs for each 
cotransfected lysate, with at least three experiments performed in duplicate for each lysate 
(Excel, Microsoft) (Figure 4-9). For the single-tail Z-test, a z-score greater than 1.645 
corresponds to a p-value less than 0.05. The alpha level used for each statistical test was 0.05.  
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2.3.6 Statistical comparison of SBA data sets 
The data obtained using anti-GPCR capture Abs was compared to the data obtained using 
the epitope-tag capture methods. Based on the data set for GPCR-RAMP complexes derived 
from the epitope-tag capture Abs, a matrix of hypothetical outcomes for the data set derived from 
the anti-GPCR Ab capture strategy was constructed (Figure 4-10). We then compared the two 
matrices of results (epitope-tag Ab capture versus protein-specific Ab capture) by converting 
them to binary score matrices (0,1). A Z-score threshold of 1.645 was applied for the anti-GPCR 
Ab data set, which corresponds to a confidence interval of 95% for a single-tailed test (Figure 4-
9). The threshold used to convert the summarized and normalized epitope tag data to binary form 
was increased by an interval of 0.125 (Table 4-4). The following metrics were plotted as a 
function of the threshold used to convert the epitope tag data to a binary matrix: (1) overall 
percent agreement (P0), (2) the percent of hits from the epitope tag data that are also found in the 
anti-GPCR Ab data (sensitivity), (3) the percent of non-hits from the epitope tag data that are 
also non-hits in the anti-GPCR Ab data (specificity), (4) the probability of a positive result in the 
anti-GPCR Ab data also being a positive in the epitope tag data (positive predictive value), (5) 
the probability of a negative result in the anti-GPCR Ab data also being a negative in the epitope 
tag data (negative predictive value) and (6) the similarity of the two data sets (Jaccard Index).  
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Table 2-2. Formulas used to compare SBA data sets. TP, true positive; TN, true negative; FP, 
false positive; TP, true positive.  
Metric Formula Information 
P0 (TP+TN)/(TP+TN+FP+FN) Overall percent agreement 
Sensitivity TP/(TP+FN) Percent of all positives from epitope beads that the anti-GPCR beads detect 
Specificity TN/(TN+FP) Percent of all negatives from epitope beads that the anti-GPCR beads detect 
Positive Predictive 
Value TP/(TP+FP) 
Probability of being a positive from epitope beads 
if anti-GPCR beads says positive 
Negative Predictive 
Value TN/(TN+FN) 
Probability of being a negative from epitope 
beads if anti-GPCR beads says negative 
Jaccard Index TP/(TP+FP+FN) Similarity of positives between the epitope beads and the anti-GPCR beads 
2.4 Proximity ligation assay (PLA) experiments 
2.4.1 Cell culture and transfection 
HEK293T cells were maintained in DMEM-Q (Thermo Fisher) with 10% FBS (Atlanta 
Biologicals). Gelatin-coated coverslips were placed within the wells of a 6-well dish with one 
well per transfection condition. HEK293T cells were seeded at 100,000 cells/mL and allowed to 
grow for 24 hours before transfection. The cells were transfected with 0.4 µg (except in one 
experiment where 0.5 µg was used) of pcDNA3.1(+) vector encoding the GPCR and RAMP2 
constructs. The total amount of DNA used for each transfection was brought to 2 µg with an 
empty pcDNA3.1(+) vector. For the mock transfection, 2 µg of empty pcDNA3.1(+) vector was 
used. Transfection was performed with 4 µL Lipofectamine 2000 per well of the 6-well dish. The 
total volume of media per well was maintained at 2 mL. 
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2.4.2 PLA procedure 
After 24 hours, cells were washed twice in PBS, fixed and permeabilized with ice-cold 
methanol for 5 mins at -20°C and then washed three times with PBS. For the formaldehyde (FA) 
fixation, cells were fixed for 10 mins at room temperature with 4% (w/v) FA (Polysciences, Inc) 
in 1x PBS, final concentration. After fixation, cells were washed three times in PBS and then 
processed following manufacturer’s instructions for DuoLink In Situ Detection Reagents Red 
Mouse/Rabbit (Sigma-Aldrich) using rabbit anti-HA (Cell Signaling Technology) and mouse 
anti-FLAG (Sigma-Aldrich) primary Abs. After PLA processing, cells were mounted in 
DuoLink mounting medium with DAPI (Sigma-Aldrich), allowed to incubate at room 
temperature, stored overnight at -20°C, and imaged the following day. 
2.4.3 PLA image acquisition 
Deconvoluted PLA images were acquired with a DeltaVision Image Restoration Inverted 
Olympus IX-71 Microscope using a 100x oil immersion objective. Excitation/emission 
wavelengths were 390/435nm for the blue channel (DAPI) and 575/632nm for the red channel 
(PLA puncta). Exposure times and transmittance percentages were held constant while imaging 
all samples within the same experiment. At least three Z-stack images (0.2 µm thickness per 
slice) of different fields of view were captured per coverslip for each control, and at least five Z-
stack images were captured for all other samples. Images from the maximum projection of Z-
stack images and Imaris spot analysis result snapshots are shown in Figure 4-13 and 4-14.  
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2.4.4 PLA image processing 
Image processing was done in ImageJ (adding scale bars, generating maximum 
projections) and Imaris. Nuclei stained with DAPI were counted to obtain the total number of cells 
per image. The PLA puncta were counted in a 3D rendering of each Z-stack in Imaris using the 
Spot tool. The same Spot parameters (estimated puncta XY and Z diameter, threshold) were used 
for all samples in all experiments. The puncta count value for each Z-stack was divided by the 
total number of cells per image, and results were plotted in Prism 8 (Graphpad).  
2.4.5 PLA data analysis 
A one-way ANOVA followed by Dunnett’s multiple comparisons test was used to 
compare the mean PLA puncta count of the positive condition (CALCRL-RAMP2, both primary 
Abs) to that of each of the controls, and to compare CXCR3-RAMP2 and mock to the other 
GPCR-RAMP2 pairs (Fig. 4-14) (Prism 8, Graphpad). Outliers from each GPCR-RAMP pair 
were determined in Prism via the ROUT method with Q=1%. Two outliers were removed from 
the PTH1R-RAMP2 data set and three from the CXCR3-RAMP2 data set (Fig. 4-14). A two-
tailed P-test in Prism was used to compare the numbers of PLA puncta from methanol-fixed and 
FA-fixed cells (Figure 4-13). Significance was determined by P<0.05. The alpha level used for 
each test was 0.05. 
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CHAPTER 3. Global Coexpression and Coevolution of RAMPs with GPCRs. 
3.1 Introduction 
Whether RAMP interactions are frequent among GPCRs outside the secretin-like family 
remains an open question. With hundreds of non-olfactory GPCRs in the human genome, 
pairwise biochemical experiments to determine whether additional GPCRs interact with each 
RAMP would be both time and resource consuming. The standard high-throughput, biochemical 
methods to identify protein-protein interactions are not amenable to GPCR-RAMP complexes 
(86). Thus, we decided to take a bioinformatics approach to test our hypothesis that RAMPs 
interact globally with GPCRs by using two complementary approaches, coexpression and 
coevolution. 
One method to elucidate protein-protein interactions (PPIs) is to evaluate the 
coexpression of two gene pairs. Physiological PPIs are expected to exist in the same cells, also 
known as "guilt-by-association."  Interacting proteins have a higher correlation of expression 
across tissues in comparison to random gene pairs (87). In addition, coexpression is often used to 
validate results from high-throughput, biochemical experiments identifying novel PPIs to reduce 
the rate of false positives (88). 
Another approach to elucidate PPIs is to carry out a phylogenetic analysis of protein 
sequences (Figure 3-1A). In a phylogenetic analysis, the evolutionary history of protein pairs is 
compared according to the hypothesis that interacting proteins coevolve in nature. Two methods 
can be implemented to examine phylogenetic similarities. The first identifies orthologs of two 
proteins across species with the assumption that interacting proteins are expected to coexist in 
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genomes (89). The second method compares the evolutionary history of each pair member while 
assuming similar phylogenetic trees (i.e., similar mutational rate) for interacting proteins. 
Phylogenetic tree similarities can be calculated by either pair-wise correlation or comparison of 
phylogenetic tree shape. Pair-wise correlation calculates the rate of mutations across species. 
Mutations in one interacting protein are expected to be coupled to mutations in the other 
interacting protein and thus, interacting proteins display a similar rate of mutations (82). For 
comparison of phylogenetic tree shape, coevolution of gene pairs is calculated by how the nodes, 
or species, are partitioned on a phylogenetic. Trees will similar branching patterns, or shape, 
show high coevolution (5). Phylogenetic analysis of protein sequences has previously been 
shown to correspond to experimentally determined PPIs (90).  In all, we address four different 
questions using the coevolution and coexpression analyses (Table 3-1). 
Table 3-1. Questions addressed by coexpression and coevolution measurements. 
Question Measurement 
Are RAMPs and GPCRs found in the same tissues? Coexpression 
Are GPCRs and RAMPs found in the same species? Percent of shared species 
Do GPCRs and RAMPs demonstrate similar mutational rates between species? Pair-wise correlation 
Do GPCRs and RAMPs have similarly shaped phylogenetic trees? Phylogeny comparison 
If RAMPs interact globally with GPCRs, then we would expect to identify higher 
coexpression and coevolution between GPCR-RAMP gene pairs in comparison to random pairs 
of genes. To ensure that strong coexpression and coevolution is indicative of protein interactions, 
we also examined the coexpression and coevolution of known pairs of interacting proteins - 
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proteins in same receptor complex and receptor-ligand pairs (91, 92). For most GPCR-RAMP 
interacting pairs, interaction is not a requirement for the GPCR to signal in response to agonist 
ligand. Thus, we expected that the coexpression and coevolution of RAMP-GPCR pairs would 
be less significant than receptor complex or receptor-ligand gene pairs (Figure 3-1B). Since 
olfactory GPCRs constitute the largest group of GPCRs and would thus dominate the outcome of 
the coevolution measurements, we excluded them in the analyses. 
Figure 3-1. Estimates of coevolution and coexpression. (A) A method to calculate coevolution
determines the number of species (grey shade) that two proteins share (red outline). Between 
species that share two proteins, the phylogenetic trees of gene pairs are compared by a 
phylogenetic comparison algorithm or by pair-wise correlation. (B) We hypothesized that 
RAMPs will show an intermediate level of coevolution and coexpression when compared to 














3.2 Coexpression analysis 
3.2.1 Expression of RAMPs in human tissues 
Northern blot analysis first showed that at least one RAMP isoform is expressed in seven 
different human and mouse tissues (93). More recently, RNA-Seq databases have been 
developed to evaluate gene expression in a much wider variety of human tissues. To examine 
RAMP expression in human tissues, I accessed an RNA-Seq database of 53 distinct tissues from 
the Genotype-phenotype consortium (GTEx). The GTEx RNA-Seq database is comprised of 
8,555 samples from 53 tissues provided by 544 human donors (94). I found that RAMPs are 
ubiquitously expressed across human tissues, with the exceptions of whole blood, transformed 
fibroblasts and lymphocytes (Figure 3-2) (41). In comparison to RAMP2 and RAMP3, RAMP1 
mRNA is more abundantly found in brain tissues and both male and female reproductive organs. 
RAMP2 and RAMP3 show higher transcript levels in adipose tissues, lung, thyroid, and breast 
tissues than RAMP1. Overall, the mRNA expression levels of RAMPs in human tissues revealed 
that RAMP2 and RAMP3 show a more similar expression pattern than with RAMP1. 
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Figure 3-2. Expression of RAMP1, RAMP2, and RAMP3 in human tissues. Transcript levels 
reported as transcripts per kilobase million (TPM) from 53 human tissues are represented as a 
heatmap. RNA-Seq data were obtained from the GTEx Consortium (94). 
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3.2.2 Normalization of RNA-Seq data sets 
We hypothesized that transcripts of interacting proteins would tend to be coexpressed 
across human tissues. Thus, I calculated the coexpression for random, receptor-complex, and 
receptor-ligand gene pairs. To account for different statistical properties of the RNA-Seq datasets 
between each sample, I normalized the data sets by four commonly used methods - quantile 
normalization, rank, transcripts per kilobase million (TPM), and reads per kilobase million 
(RPKM) (95). Following normalization, I found the median expression of each gene in each 
tissue to account for differences in the number of samples for each tissue type and then 
calculated the correlation coefficient by the Spearman method. For receptor-complex gene pairs, 
each normalization method showed significantly higher correlation than random gene pairs. 
However, receptor-ligand gene pairs showed significantly higher correlation only when quantile 
or rank normalization was used (Figure 3-3). Quantile normalization reduces unwanted technical 
variability from RNA-Seq data and was used for further analysis (96). 
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Figure 3-3. Normalization methods used prior to calculation of coexpression. 
Boxplots of coexpression, measured as Spearman rho, across 8,555 samples derived from 53 
tissues between protein pairs. Normalization methods used were (A) quantile, (B) rank order, (C) 
transcripts per kilobase million (TPM), and (D) reads per kilobase million (RPKM). These 
boxplots are shown for 500 randomly chosen gene pairs (grey), gene pairs that are members of 
the same receptor complex (green) or receptor-ligand gene pairs (blue). The boxplot shows the 
median (red line), 95% confidence interval (notch edge), 25th and 75th percentiles (box edges),
two standard deviations (whiskers) and 95% confidence interval of the median for random gene 
pairs (grey bar). Data were obtained from the GTEx database (94). Asterisks denote that the 




































































3.2.3 Global coexpression between RAMPs and GPCRs  
 
 I next searched for evidence supporting global GPCR-RAMP interactions at the RNA 
expression level. I first calculated the coefficient of expression correlation (Spearman rho) 
between each RAMP and CALCRL, a well-validated interacting GPCR (97). As expected, each 
RAMP had positive correlation with CALCRL (Figure 3-4A to C) with a Spearman rho of 0.21, 
0.84 and 0.82 for RAMP1, RAMP2 and RAMP3 respectively. Next, the expression correlation 
was calculated for the following groups – random pairs, RAMP1-GPCR, RAMP2-GPCR, 
RAMP3-GPCR, receptor-ligand, and receptor-complex. Random gene pairs showed an averaged 
correlation coefficient close to zero, while receptor-complex and receptor-ligand gene pairs had 
an average Spearman rho of 0.12 and 0.26, respectively. Each RAMP also showed a significantly 
higher correlation coefficient with GPCRs than expected by chance, with a Spearman rho of 
0.83, 0.85, and 0.83, for RAMP1, RAMP2 and RAMP3, respectively (Figure 3-4D).  
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Figure 3-4. Coexpression between GPCRs and RAMPs across human tissues. Scatterplot of
quantile normalized expression data for (A) RAMP1 (B) RAMP2 and (C) RAMP3 versus 
CALCRL. Spearman rhos are 0.21, 0.84, and 0.82 for A-C respectively. (D) Boxplot (as in 
Figure 3-3) of coexpression, measured as Spearman rho, across 8,555 samples derived from 53 
tissues between protein pairs. This boxplot is shown for 500 randomly chosen gene pairs (grey), 
RAMP1, RAMP2 or RAMP3 against non-olfactory GPCRs (orange), gene pairs that are 
members of the same receptor complex (green) or receptor-ligand gene pairs (blue). Data were 
obtained from the GTEx database (94). Asterisks denote that the median differs from that of 
randomly chosen proteins pairs, with P<0.05 (one-way ANOVA with Bonferroni correction).  
GPCRs are subdivided into families (see Figure 1-2) and further subdivided into clusters 
that reflect the molecular composition of their activating ligands (19). Specific clusters of 
GPCRs may drive the overall positive correlation between RAMPs and GPCRs. Thus, I 
calculated the expression correlation of RAMPs with each cluster of GPCRs and found that a 
select set of GPCR clusters showed significantly higher median expression correlation with 
RAMPs in comparison to RAMPs with all GPCRs. The melanin-concentrating hormone (MCH) 
GPCR cluster has the highest averaged coexpression with RAMP1, followed by the amine 
cluster. RAMP2 and RAMP3 have the highest coexpression with prostaglandin receptors, 
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variety of agonists - small molecules (purine and amine GPCRs), lipids (prostaglandin GPCRs), 
and peptides (MCH and chemokine receptors). Although the secretin GPCR cluster has been the 
most well-studied in respect to RAMP interaction, the coexpression between secretin-like 




Figure 3-5. Coexpression between different GPCR clusters and RAMPs. Boxplot (as in Figure 
3-3) of Spearman rhos across 53 human tissues between (A) RAMP1 (B) RAMP2 (C) RAMP3 
and non-olfactory GPCRs. Data were obtained from the GTEx database (94). Receptor clusters 
with significantly higher coexpression than all GPCRs are highlighted with purple. 
Abbreviations: MCH, melanin-concentrating hormone; MECA, melanocortin, endothelial 




3.2.4 Coexpression of RAMP2 and RAMP3 with similar GPCRs 
 
I found that RAMP2 and RAMP3 are expressed in similar tissues and show high 
coexpression with the same clusters of GPCRs (Figure 3-2 and Figure 3-5). Thus, I was 
interested if RAMP2 and RAMP3 are coexpressed with similar GPCRs. As expected, RAMP2 
and RAMP3 showed a similar pattern of coexpression with individual GPCRs and are thus 
coexpressed with similar sets of GPCRs. (Figure 3-6C). No clear pattern was observed between 
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the coexpression of RAMP1 with GPCRs and the coexpression of RAMP2 and RAMP3 with 
GPCRs (Figure 3-6A and B). 
Figure 3-6. Similarity of coexpression between RAMPs with GPCRs. Scatterplots of Spearman
rho values between (A) RAMP1 and each GPCR versus RAMP2 and each GPCR and similarly 
for (B) RAMP1 versus RAMP3 and (C) RAMP2 versus RAMP3. Each dot represents the 
Spearman rho value between the indicated RAMP and an individual GPCR. Data were obtained 
from the GTEx database (94). 
3.3 Coevolution of RAMPs with GPCRs 
3.3.1 GPCR and RAMP orthologs across species 
All eukaryotes express GPCRs, while a subset of eukaryotes, the chordates/vertebrates, 
express RAMPs. Thus, the orthologs of both genes are expected to be found exclusively in 















the OMA groups and genomic sequences from the OMA database, which includes genomes for 
1970 organisms (18). OMA groups are sets of genes from various organisms which are bona fide 
orthologous to each other. These sets of genes that have been determined to relate by speciation 
events, and thus, there is at most one gene per species assigned to an OMA group. In the case of 
bony fish species, which encode two genes for RAMP1 and RAMP2, the most genetically distant 
RAMP is not included in the OMA group. In total, 44 of the 1970 species had OMA groups that 
included at least one ortholog of a human GPCR and an ortholog of a human RAMP. As 
expected, all species were members of the Chordata phylum. The Mammalia, Actinopteri and 
Aves classes constituted 79%, 9%, and 7%, respectively, of the species that had both a human 
GPCR and RAMP ortholog. However, more genomic data for more mammalian species were 
available in comparison to the Actinopteri and Aves classes. 
3.3.2 Percent shared species between RAMPs and GPCRs 
We next calculated the percent of shared species between groups of gene pairs as the 
fraction of the shared species from the joint list of species for both genes in the species pair. 
Percent shared species was calculated for each RAMP and all non-olfactory GPCR, 500 
randomly chosen protein-coding gene pairs, and genes encoding known protein-protein 
interactions. As expected, the protein complex and ligand-receptor gene pairs showed significant 
signal, with 2.4- and 2.1- fold higher percentages of shared species than random gene pairs. The 
pairs of all three RAMPs with GPCRs showed significant, 1.6- to 1.8- fold higher percentage of 
shared species than expected by chance (Figure 3-7A). 
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3.3.3 Comparison of phylogenetic trees between RAMPs and GPCRs 
We next calculated the estimated gene pair coevolution by comparing the phylogenetic 
trees of gene pairs across organisms that have orthologs for both examined genes. The average 
number of examined organisms that we built and compared the phylogenetic trees was 16.5, with 
a standard deviation of 7.5. For each GPCR-RAMP pair, we only compared phylogenetic trees 
that that shared more than five species (96% of pairs). The orthologous amino acid sequences 
across species were first aligned using the BLOSUM50 scoring matrix, which is based on local 
alignments (98).  Then a matrix of pairwise sequence distance, or the evolutionary rate of change 
between two gene pairs, was calculated using the Jukes-Cantor algorithm (99). Two methods for 
comparing phylogenetic trees were then used. The first method compares the manner in which 
each tree partitions its nodes (species), or how many branches have a similar topology (81). 
Species are partitioned within a gene’s phylogenetic tree based on the number of amino acid 
differences between gene orthologs. The output of this method is a percent similarity score, or 
phylo-comparison score. We found that the phylogenetic correlation coefficient for each RAMP 
with GPCRs, receptor-complex gene pairs, and receptor-ligand gene pairs was significantly 
higher than random pairs (Figure 3-7B). 
The second method, pair-wise correlation, calculates the Pearson correlation between 
distance matrices, or a correlation of the mutational rate of two gene pairs between shared 
species. Before calculating the pair-wise correlation, we normalized mutational rates to the "tree 
of life" with the 18S ribosomal RNA (rRNA). Normalization to the 18S rRNA gene reduces the 
"background" similarity resulting from amino acid changes due to speciation and enables the 
specific protein pair to govern the correlation strength. The output of the pair-wise correlation 
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method is a Pearson correlation coefficient, or phylogenetic correlation coefficient. We found 
that the phylogenetic correlation coefficient for each RAMP with GPCRs and receptor complex 
gene pairs, but not receptor-ligand pairs, was significantly higher than random pairs (Figure 3-
7C). The phylogenetic analysis was repeated across mammalians, but without normalization by 
18S rRNA distance. In this case, the pairs of each RAMP with GPCRs, but not those of receptor 
complexes and receptor-ligand pairs showed significantly higher correlation coefficient than that 
expected by chance (Figure 3-7D). 
Figure 3-7. Shared species and phylogenetic tree comparison between GPCRs and RAMPs. (A)
Boxplot for percent of shared species for gene pairs. (B) Boxplot for the global phylogenetic 
score as calculated by phylo-comparison for all GPCRs. (C) Boxplot for the phylogenetic 
correlation coefficient across all organisms, normalized by 18S rRNA sequence distance. (D) 
Boxplot for phylogenetic correlation coefficient across mammalians alone. Boxplots (as in 
Figure 3-3) are shown for 500 randomly chosen gene pairs (grey), RAMP1, RAMP2 or RAMP3 
against non-olfactory GPCRs (orange), gene pairs that are members of the same receptor 
complex (green) or receptor-ligand gene pairs (blue). Asterisks denote that the median differs 

























































































































































































Previous studies have shown that eleven GPCRs, mostly focusing on the secretin-like 
receptors, interact with one or more RAMPs. Here, we address whether additional GPCRs also 
interact with RAMPs. We used computational methods to assess the coexpression and 
coevolution of all non-olfactory GPCRs with each RAMP on a global scale. Coevolution and 
coexpression of two genes suggest that the proteins they encode interact, whether directly or 
indirectly. Our findings show that GPCRs and RAMPs are significantly coevolved and 
coexpressed, suggesting that more GPCRs interact with RAMPs than is currently appreciated. 
To ensure that the four methods we used – coexpression, percent shared species, tree 
comparison, and pair-wise tree correlation – could detect protein-protein interactions on a global 
level, we first compared the signal from known interacting gene pairs to random gene pairs. We 
found that each of the four methods implemented successfully identified protein-complex and 
protein-ligand coexpression and coevolution on a global level. The RAMP-GPCR gene pairs also 
demonstrated significant signal from each computational method implemented, but this signal 
was generally lower than that of known interacting protein pairs. The weaker signal is likely 
related to the previous findings that (i) not all GPCRs interact with a RAMPs and/or (ii) GPCRs 
that do interact with RAMPs often do not require complex formation to respond to known 
endogenous ligands. 
To determine coexpression, I analyzed 8,555 human transcriptomes across 53 distinct 
tissues from data provided by the GTEx consortium. I found that RAMPs are ubiquitously 
expressed in the human body, as previously shown by northern blot analysis (93). I also 
identified higher gene coexpression across human tissues for GPCRs and RAMPS than predicted 
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by chance. The high gene coexpression was driven by a subset of rhodopsin-like GPCR clusters, 
which included GPCRs that respond to a variety of different ligands. Thus, it is likely that 
additional rhodopsin-like GPCRs interact with RAMPs. To date, the only reported RAMP-
interacting GPCR in the rhodopsin-like family is GPER1 (9). 
While the coexpression analyses provide a global overview of RAMP-GPCR interaction, 
we would also surmise that known interacting GPCRs demonstrate a positive correlation with 
cognate RAMPs. As expected, I found that the most well-studied RAMP-interacting GPCR, 
CALCRL, shows a positive correlation with each RAMP. In agreement with our coexpression 
analysis with RNA-Seq data, a coexpression analysis using microarray data shows that RAMP2 
and CALCRL have high expression correlation in human tissues (100). 
Multiple RAMPs often interact with the same GPCR, which could have implications for 
the regulation of RAMP-GPCR complex formation (97). In this study, I found that RAMP2 and 
RAMP3 have similar tissue distribution, high coexpression with the same clusters of GPCRs, 
and the strong correlation of Spearman rhos for each GPCR. These observations are in line with 
my later findings (see Chapter 4) showing that interacting GPCRs either form complexes with all 
three RAMPs or with just RAMP2 and RAMP3. Given that RAMP2 and RAMP3 are expressed 
in similar tissues and appear to interact with similar GPCRs, it is plausible that RAMP2 and 
RAMP3 may modulate the activity of each other by competing for specific GPCRs. 
All three methods that we employed for estimation of gene coevolution – percent shared 
species, tree comparison, and pair-wise tree correlation – showed similar, identifiable 
coevolution among each of the RAMPs and non-olfactory GPCRs. The percent shared species 
analysis provides the most basic estimate of coevolution because it shows the tendency of a gene 
pair to exist in the same species. It is important to note that CALCRL is more evolutionarily 
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ancient than the RAMP family of proteins. RAMPs are found only in vertebrates, while the 
calcitonin subfamily of receptors can be found in invertebrate species such as Drosophila 
melanogaster and Caenorhabditis elegans. Therefore, CALCRL in invertebrate species likely 
functions without RAMPs (100). This situation could cause the percentage of shared species to 
be more modest even in cases of interacting protein pairs.  Thus, coexpression and coevolution 
measured by pair-wise tree correlations and tree comparison may be a better indicator of 
interaction because these methods consider only species that contain both a RAMP and GPCR.  
In vitro, high-throughput protein-protein interactions can be probed by direct chemical 
assays, including yeast two-hybrid and tandem mass spectrometry (101, 102). However, GPCRs 
are not amenable to these high-throughput methods. In large protein networks or families, such 
as GPCRs, it is impractical to study all possible biochemical interactions in a pair-wise manner. 
Thus, the use of bioinformatics methods, such as assessing coexpression and coevolution, are 
useful. Computational approaches also have the advantage that they are independent of the 
quality and validation of antibody affinity or other technical parameters that are required to carry 
direct experimentation. However, computational methods, as well as in vitro methods, are 
subject to limitations, including false detection (“false positives”) and misdetection (“false 
negatives”). Thus, any potential interaction should be validated by multiple methods. 
In summary, our results support the hypothesis that a global GPCR-RAMP interaction 
map exists. First, RNA-Seq data revealed that RAMPs are ubiquitously expressed across human 
tissue types, suggesting that RAMPs are essential to many physiological functions. Second, we 
determined that RAMPs are significantly coexpressed and coevolved with GPCRs. We also 
determined a high level of correlation between coexpression coefficients of RAMP2 and RAMP3 
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with each GPCR. These results imply that more GPCRs interact with RAMPs than what is 
currently reported. 
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CHAPTER 4. Multiplexed Analysis of the Secretin-like GPCR-RAMP Interactome 
4.1 Introduction 
We next wanted to use a direct biochemical assay to determine which GPCRs interact 
with RAMPs. Given that there are ~400 non-olfactory GPCRs that might, in principle, interact 
with each of the three RAMPs, the ideal experimental system should be high-throughput and 
provide a quantitative assessment of GPCR-RAMP complexes. Towards this end, I employed a 
suspension bead array (SBA) approach. The SBA strategy is based on the use of magnetic 
microspheres with different bar-codes. Each bar-coded bead population is coupled to a specific 
antibody (Ab), allowing the parallel capture and detection of multiple unique, identifiable protein 
epitopes from a complex mixture of proteins in solution. The SBA technology, in combination 
with the Human Protein Atlas (HPA) Ab collection, has been successfully implemented to 
identify soluble proteins in human serum samples (85, 103). Here I demonstrate an experimental 
approach to define the secretin-like GPCR-RAMP interactome and develop an assay capable of 
testing the hypothesis that GPCRs and RAMPs interact on a global level. 
4.2 Design and validation of GPCR and RAMP constructs 
4.2.1 Design of GPCR and RAMP constructs 
Immunoassays, such as a suspension bead array, require the use of validated Abs. 
However, GPCR Abs are notoriously difficult to produce because of the sequence similarity 
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amongst species and cross-reactivity between closely related GPCRs (24). In addition, Abs to 
RAMPs have not been adequately validated (97). To overcome the issue of using protein-specific 
Abs, I created dual, epitope-tagged RAMP, secretin-like GPCR, and ADGRF5 DNA constructs. 
Constructs of the chemokine receptors were developed for previous studies in our lab (104–106). 
Each of the three RAMPs was tagged with a FLAG epitope and OLLAS epitope at its N- and C-
terminal tail, respectively (107). Each of the 23 GPCRs was epitope-tagged at its N-terminal tail 
with an HA epitope and/or at its C-terminal tail with a 1D4 epitope (Figure 4-1).  
Figure 4-1. Epitope-tagged GPCR and RAMP DNA constructs. The GPCR constructs have an 
N-terminal HA tag, and a C-terminal 1D4 tag. The RAMP constructs have an N-terminal FLAG 
tag and a C-terminal OLLAS tag. 
4.2.2 Validation of GPCR and RAMP constructs 
To ensure that the epitope tags added onto the RAMP and GPCRs did not alter 
functionality, I ran a battery of tests. To begin with, I determined that the dual-epitope secretin-
like GPCR and ADGRF5 were expressed in HEK293F cells, as detected by immunoblot using 
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anti-1D4 and anti-HA mAbs (Figure 4-2A). Dual-tagged RAMP constructs expressed in 
HEK293F cells were detected by immunoblot using anti-FLAG and anti-OLLAS Abs (Figure 4-
2B). RAMPs traffic to the cell surface when co-expressed with CALCRL (41). Thus, I 
determined the cell surface localization of each RAMP construct expressed alone or coexpressed 
with CALCRL by flow cytometry using an anti-FLAG Ab. As expected, each RAMP constructs 
demonstrated an increase in cell surface localization upon coexpression with CALCRL (Figure 
4-2C). Finally, we compared the ability of adrenomedullin to induce cAMP accumulation in cells 
expressing dual-tagged CALCRL alone, CALCRL with coexpression of dual-tagged RAMP2 or 
CALCRL with coexpression of untagged RAMP2. No cAMP accumulation was observed in 
cells transfected with vector, dual-tagged CALCRL or dual-tagged RAMP2. A similar dose-
response curve was observed in cells coexpressing dual-tagged CALCRL with either untagged 
RAMP2 or dual-tagged RAMP2 (Figure 4-2D). Therefore, the epitope tags on RAMP2 and 
CALCRL do not affect the ability of the CALCRL-RAMP2 heterocomplex to respond to the 
agonist adrenomedullin through stimulation of cAMP production. Taken together, these 
experiments indicate that the epitope tags do not affect functionality of RAMPs or CALCRL.  
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Figure 4-2. Expression and function of epitope-tagged GPCRs and RAMPs. (A) Dual-tagged 
GPCRs expressed in HEK293F cells were detected by immunoblot with an anti-HA Ab (green) 
and anti-1D4 Ab (red). (B) Dual-tagged RAMPs expressed in HEK293F cells were detected by 
immunoblot using an anti-FLAG Ab (green) or anti-OLLAS Ab (red). (C) Cell surface 
localization of each FLAG-RAMP-OLLAS expressed in HEK293F cells alone (solid bar) or 
coexpressed with HA-CALCRL-1D4 (striped bar) was measured by flow cytometry using an 
anti-FLAG Ab conjugated to PE. (D) Adrenomedullin-induced cAMP accumulation was 
measured in HEK293T cells expressing pcDNA3.1(+), RAMP2 alone, HA-CALCLRL-1D4 
alone, HA-CALCRL-1D4 plus RAMP2, or HA-CALCRL-1D4 plus FLAG-RAMP2-OLLAS.  
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4.3 SBA analysis of GPCR-RAMP complexes 
4.3.1 Selection of GPCRs to screen for RAMP interaction 
To adapt the SBA method and develop an assay to measure GPCR-RAMP interactions, I 
focused on the family of 15 secretin-like GPCRs, and eight additional GPCRs, to screen for their 
ability to interact with each of the three RAMPs. All of the secretin-like receptors were included 
in the test set because this GPCR family encompasses the majority of GPCR-RAMP interactions 
described to date. Based on an earlier coevolution and coexpression analyses, we also included 
GPR4 and GPR182 from the rhodopsin-like GPCR family and ADGRF5 from the adhesion 
GPCR family (108). In addition, the chemokine cluster of GPCRs demonstrated a significantly 
higher median coexpression with RAMP2 and RAMP3 in comparison with all GPCRs (Figure 3-
5). Thus, we included members of the chemokine receptor family: C-C chemokine receptor 5 
(CCR5), C-C chemokine receptor 7 (CCR7), C-X-C chemokine receptor 3 (CXCR3), C-X-C 
chemokine receptor 4 (CXCR4), and atypical chemokine receptor 3 (ACKR3), also known as C-
X-C chemokine receptor 7 (CXCR7). A list of each of the 23 GPCRs chosen for SBA analysis 
and the epitope tag(s) present on each GPCR construct is presented in Table 4-1. 
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Table 4-1. A list of 23 GPCRs included in this study. Included are the common abbreviations of 
each GPCR, GPCR family designation, and engineered epitope tag on the N- and C-terminal 
tails. GPCRs are listed in alphabetical order. Secretin-family receptors are shown in bold. Y, yes; 
N, No.  







Atypical chemokine receptor 3/ 
C-X-C chemokine receptor 7 
ACKR3/ 
CXCR7 Rhodopsin Y Y 
Pituitary adenylate cyclase-
activating polypeptide type 1 ADCYAP1R1 Secretin Y Y 
Adhesion G protein-coupled 
receptor F5 ADGRF5 Adhesion Y Y 
Calcitonin receptor-like receptor CALCRL Secretin Y Y 
Calcitonin receptor CALCR Secretin Y Y 
C-C chemokine receptor type 5 CCR5 Rhodopsin N Y 
C-C chemokine receptor type 7 CCR7 Rhodopsin N Y 
Corticotropin-releasing hormone 
receptor 1 CRHR1 Secretin Y Y 
Cortocotropin-releasing 
hormone receptor 2 CRHR2 Secretin Y Y 
C-X-C chemokine receptor type 3 CXCR3 Rhodopsin Y N 
C-X-C chemokine receptor type 4 CXCR4 Rhodopsin N Y 
Gastric inhibitory polypeptide 
receptor GIPR Secretin Y Y 
Glucagon receptor GCGR Secretin Y Y 
Growth hormone releasing 
hormone GHRHR Secretin Y Y 
Glucagon-like receptor 1 GLP1R Secretin Y Y 
Glucagon-like receptor 2 GLP2R Secretin Y Y 
G protein-coupled receptor 4 GPR4 Rhodopsin Y N 
G protein-coupled receptor 182 GPR182 Rhodopsin Y N 
Parathyroid hormone receptor 1 PTH1R Secretin Y Y 
Parathyroid hormone receptor 2 PTH2R Secretin Y Y 
Secretin receptor SCTR Secretin Y Y 
VIP and PACAP receptor 1 VIPR1 Secretin Y Y 
VIP and PACAP receptor 2 VIPR2 Secretin Y Y 
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I aimed to create an SBA comprising a set of both GPCR-specific and RAMP-specific 
Abs, as well as monoclonal antibodies (mAbs) against epitope tags that were engineered onto 
expressed GPCR and RAMP constructs. The complete list of all anti-GPCR and anti-RAMP Abs 
coupled to the beads is presented in Table 4-2. A total of 55 Abs from the HPA were available to 
target 21 of the 23 GPCRs in the test set. The HPA Abs were produced by using 50 to 150 
amino-acid-long peptides as immunogens to raise rabbit polyclonal Abs (109). The nine anti-
RAMP Abs employed were obtained from the HPA and various commercial sources. In addition, 
beads were coupled to four, validated anti-epitope tag mAbs (anti-HA, anti-1D4, anti-FLAG, and 
anti-OLLAS) (107, 110). These four beads were included to capture GPCRs or RAMPs that were 
engineered to contain an epitope-fusion tag (Figure 4-1). For controls, we used rabbit IgG, 
mouse IgG, and uncoupled beads. The final SBA comprised 70 unique Abs coupled to unique 
bead IDs, and pooling created the basis for the multiplex assay (Figure 4-3A). 
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Table 4-2. The specific Abs coupled to a unique bead ID. Also included are the source of the Ab, 
and product code. The labels in bold correspond to secretin-like GPCRs. Underlined product codes 
indicate validated Abs.  
Bead 













61 GLP2R HPA HPA027929 321 ADGRF5 HPA HPA065251 
72 VIPR1 HPA HPA046516 325 GHRHR HPA HPA068576 
73 CRHR2 HPA HPA046683 326 ADGRF5 HPA HPA068796 
74 ADCYAP1R1 HPA HPA030739 334 PTH1R HPA HPA075879 
75 ACKR3 HPA HPA049718 336 GLP1R HPA HPA077988 
77 ACKR3 HPA HPA032003 337 GPR182 HPA HPA027037 
78 CRHR1 HPA HPA063352 343 Empty N/A N/A 
79 GCGR HPA HPA066333 339 VIPR1 HPA HPA026777 
80 GIPR HPA HPA068054 349 RAMP2 HPA HPA064452 
81 CXCR4 HPA HPA068321 350 rabbit IgG Bethyl P120 
82 GCGR HPA HPA071228 355 RAMP1 Abcam ab156575 
83 CCR5 HPA HPA070587 356 RAMP1 HPA HPA010654 
84 CXCR4 HPA HPA051623 357 RAMP2 HPA HPA052020 
85 CRHR1 HPA HPA055287 358 RAMP1 HPA HPA057814 
86 CRHR1 HPA HPA071484 359 OLLAS In house N/A 
87 CRHR2 HPA HPA073345 360 FLAG Sigma F3165 
88 ADCYAP1R1 HPA HPA073908 361 RAMP1 RnD AF6428 
89 ACKR3 HPA HPA057492 362 RAMP2 RnD AF6427 
90 GHRHR HPA HPA077545 363 RAMP3 RnD AF4875 
91 VIPR2 HPA HPA062707 364 RAMP1 Santa 
Cruz
sc-11379 
92 GPR182 HPA HPA027037 365 mouse 
IgG
Bio Rad PMP01X 
93 GCGR HPA HPA057075 366 1D4 In house N/A 
94 CRHR1 HPA HPA046066 367 HA Biolegend 16B12 
95 GHRHR HPA HPA070884 373 CXCR3 HPA HPA003189 
96 GCGR HPA HPA074345 374 SCTR HPA HPA007269 
293 SCTR HPA HPA007312 375 PTH1R HPA HPA007491 
299 PTH1R HPA HPA007978 376 CALCRL HPA HPA007586 
300 PTH2R HPA HPA010534 377 VIPR1 HPA HPA007588 
304 CRHR1 HPA HPA032018 378 CALCRL HPA HPA008070 
306 GHRHR HPA HPA034645 379 PTH1R HPA HPA007978 
307 GHRHR HPA HPA034644 380 PTH2R HPA HPA010534 
309 CXCR3 HPA HPA045942 381 PTH2R HPA HPA010655 
313 CRHR1 HPA HPA052441 382 GIPR HPA HPA017428 
319 GLP2R HPA HPA064671 383 GPR4 HPA HPA019207 
320 GLP1R HPA HPA065175 384 CXCR4 HPA HPA027832 
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Each of the three epitope-tagged RAMP constructs was expressed in HEK293F cells 
alone or coexpressed with each of the 23 epitope-tagged GPCR constructs. Following 
transfection, each cell preparation was solubilized in a dodecyl maltoside detergent solution to 
create a heterogeneous micelle mixture of RAMPs, GPCRs and GPCR-RAMP complexes, in 
addition to other cellular protein components (Figure 4-3A). This strategy created a set of 73 
unique lysates cotransfected with each combination of the RAMPs and 23 GPCRs, plus three 
RAMP controls, and empty-vector, or mock, transfected controls.  
Next, we distributed each lysate in duplicate into 96-well plates and added aliquots of the 
pooled SBA to each well. Four replicate plates were processed in parallel, one for each detection 
mAb. For detection of the proteins or protein complexes bound to the beads, each plate was then 
incubated with a different anti-epitope tag detection mAb (a PE-conjugated version of either 
anti-HA, anti-FLAG, anti-1D4 or anti-OLLAS) (Figure 4-1). The fluorescence from the PE-
conjugated detection mAbs was measured by a flow cytometer (Luminex FlexMap 3D) and 
matched to the bar-code of each bead. The SBA strategy allowed us to evaluate protein 
expression, Ab specificity, and GPCR-RAMP complex formation in a single experiment (Figure 
4-3B). 
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Figure 4-3. Schematic of SBA procedure. (A) Unique Abs were coupled to different bar-coded 
beads to create an SBA with 70 distinct populations of capture beads, and the beads were 
subsequently pooled. DNA constructs encoding each of three epitope-tagged RAMPs and 23 
epitope-tagged GPCRs were cotransfected in HEK293F cells such that all possible combinations 
of GRCPs and RAMPs were represented. The cells were solubilized in a detergent solution, 
which resulted in heterogeneous mixtures of solubilized proteins, including the RAMPs, GPCRs, 
and putative GPCR-RAMP complexes. An aliquot of each cell lysate was incubated with an 
aliquot of SBA. Four identical assay plates were prepared in this manner. Following wash steps, 
a different PE-conjugated anti-epitope tag detection mAb was added to each of the four plates. 
(B) A Luminex 3D FlexMap instrument was used to measure the reporter fluorescence produced 
by the PE-conjugated detection mAb while simultaneously reading the bar-code of each 
individual bead. From a single well, the specificity of RAMP Abs and GPCR Abs could be 
determined. Simultaneously, GPCR-RAMP complexes could be captured using either anti-
epitope tag Abs, anti-GPCR Abs, or anti-RAMP Abs
64 
65 
4.3.2 Capture and detection of RAMPs and GPCRs using anti-epitope tag mAbs. 
We first determined that the epitope-tagged GPCRs and RAMPs could be captured and 
detected by mAbs targeting the epitope tags. Expression of each dual-epitope tagged RAMP was 
demonstrated by capture with one of the anti-epitope tag mAb beads (OLLAS or FLAG) and 
detection with the PE-conjugated version of the other anti-epitope tag mAb (OLLAS or FLAG) 
(Figure 4-4A and B). Similarly, expression of each dual-epitope tagged GPCR was demonstrated 
by capture and subsequent detection with the anti-1D4 and anti-HA mAbs (Figure 4-4C and D).  
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Figure 4-4. Validation of epitope tag mAbs to capture and detect RAMPs and GPCRs. Lysates 
from cells transfected with each epitope-tagged RAMP construct (FLAG and OLLAS) were 
incubated with the SBA, which included mAbs targeting FLAG or OLLAS. Each RAMP was 
(A) captured with anti-OLLAS mAb beads and detected with PE-conjugated anti-FLAG mAb or 
(B) captured with anti-FLAG mAb beads and detected with a PE-conjugated anti-OLLAS mAb. 
Lysates from cells transfected with each epitope-tagged GPCR construct (HA and/or 1D4) were 
incubated with the SBA, which included mAbs targeting HA or 1D4. Each GPCR was (C) 
captured with anti-HA mAb beads and detected with a PE-conjugated anti-1D4 mAb, or (D) 
captured with anti-1D4 mAb beads and detected with a PE-conjugated anti-HA mAb. Grey 
boxes around the occasional data set indicate that the GPCR does not have both engineered 
epitope tags, and thus would not be expected to show signal in this experiment. The labels in 
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bold correspond to secretin-like GPCRs. Data is median fluorescence intensity (MFI) and 
representative of at least nine experiments performed in duplicate.  
4.3.3 Capture and detection of GPCR-RAMP complexes using anti-epitope tag mAbs 
Having validated that both GPCRs and RAMPs can be captured with one of the anti-
epitope tag beads and detected with one of four PE-conjugated, anti-epitope tag mAbs, it follows 
that we should also be able to detect GPCR-RAMP complexes that were captured by the Abs of 
the SBA. In the basic experimental setup using epitope tag mAbs, there are eight possible 
capture-detection mAb pairs that can be used to capture or detect either a RAMP or a GPCR in a 
given GPCR-RAMP complex: 1D4-FLAG, 1D4-OLLAS, HA-FLAG, HA-OLLAS, FLAG-1D4, 
FLAG-HA, OLLAS-1D4 and OLLAS-HA (Figure 4-5). For single epitope-tagged GPCRs, four 
capture-detection mAb pairs could be used to detect a GPCR-RAMP complex. Several GPCRs 
formed complexes with one or more of the RAMPs, including CALCRL. CALCRL has 
previously been shown to create a stable complex which each RAMP (111). The significance of 
the detection signal for the complex depended on the capture-detection Ab pair used (Table 4-3). 
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Figure 4-5. Capture and detection of GPCR-RAMP complexes using anti-epitope tag mAbs. 
Lysates from cells transfected with each epitope-tagged RAMP construct and cotransfected with 
each epitope-tagged GPCR construct were incubated with the SBA, which included beads that 
were conjugated to mAbs targeting the four tags. Complexes were captured in multiplex fashion 
using one of the four mAbs. There are eight possible capture-detection schemes. The GPCR is 
captured using anti-1D4 mAb, and the GPCR-RAMP complex is detected using (A) PE-
conjugated FLAG mAb or (B) PE-conjugated anti-OLLAS mAb. The GPCR is also captured 
using anti-HA mAb, and the GPCR-RAMP complex is detected using (C) PE-conjugated anti-
FLAG mAb or (D) PE-conjugated anti-OLLAS mAb. The RAMP is captured using anti-FLAG 
mAb, and the GPCR-RAMP complex is detected using (E) PE-conjugated 1D4 mAb or (F) PE-
conjugated anti-HA mAb. The RAMP is also captured using anti-OLLAS mAb, and the GPCR-
RAMP complex is detected using (G) PE-conjugated 1D4 mAb or (H) PE-conjugated anti-HA 
mAb. Data are presented for each of the three RAMPs. GPCR names are listed at the bottom of 
each RAMP panel, and the boxes are color-coded. The occasional grey box indicates that the 
GPCR did not have the appropriate epitope tag to be captured or detected. The labels in bold 
correspond to secretin-like GPCRs. 
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Table 4-3. Statistical significances of complex formation between each GPCR and RAMP
complex pair reported as p-values. The data sets are from GPCR-RAMP complexes capture and 
detected by mAbs targeting epitope tags on the GPCR and RAMP constructs (Figure 4-5). 
Statistical significance of signal between mock transfected cell lysates and lysates from cells co-
transfected with each dual-tagged RAMP construct plus each dual or single-tagged GPCR 
construct (Ordinary one-way ANOVA, Dunnett’s multiple comparisons test). N/A indicates that 
the GPCR does not have the epitope tag to be captured or detected with the corresponding Ab. 
Secretin-like receptors are shown in bold. 
Interaction with RAMP1 
Capture Ab 1D4 1D4 HA HA OLLAS OLLAS FLAG FLAG 
Detection Ab FLAG OLLAS FLAG OLLAS 1D4 HA 1D4 HA 
ACKR3 0.8796 0.8534 0.9999 0.9998 0.9994 0.9999 0.9993 0.9999
ADCYAP1R1 0.2328 0.0423 0.9998 0.9996 0.0002 0.9998 0.0001 0.9994 
ADGRF5 0.4556 0.0370 0.9999 0.9999 0.6631 0.9998 0.5635 0.9995 
CALCR 0.1073 0.0054 0.9999 0.9999 0.9835 0.9998 0.9363 0.9997 
CALCRL 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
CCR5 0.9996 0.9996 N/A N/A 0.9999 N/A 0.9999 N/A 
CCR7 0.9998 0.9995 N/A N/A 0.9999 N/A 0.9999 N/A 
CRHR1 0.9994 0.9993 0.9999 0.9998 0.9998 0.9999 0.9998 0.9998 
CRHR2 0.9457 0.8771 0.9992 0.9999 0.9883 0.9997 0.9936 0.9990 
CXCR3 0.9993 0.9854 N/A N/A 0.9993 N/A 0.9994 N/A 
CXCR4 0.9991 0.9991 N/A N/A 0.9997 N/A 0.9997 N/A 
GCGR 0.0238 0.0001 0.9999 0.9993 0.8747 0.9999 0.4756 0.9999 
GHRHR 0.3372 0.1207 0.9994 0.9996 0.1304 0.9996 0.1245 0.9993 
GIPR 0.0001 0.0001 0.6682 0.9957 0.0382 0.9946 0.0006 0.5220 
GLP1R 0.0018 0.0001 0.0613 0.4153 0.0001 0.9956 0.0001 0.6313 
GLP2R 0.0001 0.0001 0.9884 0.9995 0.0001 0.9956 0.0001 0.4058 
GPR182 N/A N/A 0.0001 0.1198 N/A 0.0390 N/A 0.0001 
GPR4 N/A N/A 0.0001 0.2359 N/A 0.0056 N/A 0.0001 
PTH1R 0.0001 0.0001 0.8781 0.5164 0.0001 0.9988 0.0001 0.8046 
PTH2R 0.0001 0.0001 0.0054 0.0423 0.0001 0.8586 0.0001 0.0933 
SCTR 0.0358 0.0001 0.9999 0.9994 0.0001 0.9869 0.0001 0.9994 
VIPR1 0.6674 0.2842 0.9999 0.9991 0.0717 0.9997 0.0142 0.9994 
VIPR2 0.0038 0.0508 0.9994 0.9999 0.5351 0.9999 0.1127 0.9997 
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Interaction with RAMP2 
Capture Ab 1D4 1D4 HA HA OLLAS OLLAS FLAG FLAG 
Detection Ab FLAG OLLAS FLAG OLLAS 1D4 HA 1D4 HA 
ACKR3 0.0001 0.0001 0.9940 0.9999 0.6094 0.9999 0.0186 0.9991
ADCYAP1R1 0.0288 0.0117 0.9999 0.9997 0.0044 0.9998 0.0001 0.9997 
ADGRF5 0.0001 0.0001 0.9997 0.9993 0.9029 0.9999 0.9181 0.9999 
CALCR 0.0001 0.0001 0.9732 0.9867 0.9442 0.9998 0.2488 0.9994 
CALCRL 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
CCR5 0.2940 0.1073 N/A N/A 0.9988 N/A 0.9944 N/A 
CCR7 0.9939 0.3372 N/A N/A 0.8242 N/A 0.9989 N/A 
CRHR1 0.0002 0.0001 0.9947 0.5879 0.9990 0.9999 0.9654 0.9995 
CRHR2 0.3328 0.0709 0.0342 0.9997 0.8729 0.9988 0.7280 0.9397 
CXCR3 0.9939 0.8620 N/A N/A 0.9997 N/A 0.9994 N/A 
CXCR4 0.9993 0.9988 N/A N/A 0.9997 N/A 0.9996 N/A 
GCGR 0.0001 0.0001 0.9997 0.9995 0.9947 0.9999 0.2862 0.9999 
GHRHR 0.0001 0.0001 0.6943 0.9999 0.7817 0.9997 0.0839 0.9988 
GIPR 0.0001 0.0001 0.0001 0.0341 0.0001 0.7177 0.0001 0.1563 
GLP1R 0.0001 0.0001 0.0064 0.6186 0.0001 0.9992 0.0001 0.9128 
GLP2R 0.0001 0.0001 0.0165 0.9859 0.0001 0.9990 0.0001 0.9935 
GPR182 N/A N/A 0.0001 0.0001 N/A 0.0197 N/A 0.0001 
GPR4 N/A N/A 0.0001 0.0006 N/A 0.0001 N/A 0.0001 
PTH1R 0.0001 0.0001 0.3975 0.9935 0.0001 0.9988 0.0001 0.6975 
PTH2R 0.0001 0.0001 0.0165 0.0572 0.0001 0.5891 0.0001 0.6220 
SCTR 0.0001 0.0001 0.9994 0.8982 0.0001 0.9949 0.0001 0.9994 
VIPR1 0.0091 0.0001 0.9989 0.9886 0.0010 0.9998 0.0001 0.9993 
VIPR2 0.0001 0.0001 0.9872 0.9741 0.0433 0.9998 0.0004 0.9993 
Interaction with RAMP3 
Capture Ab 1D4 1D4 HA HA OLLAS OLLAS FLAG FLAG 
Detection Ab FLAG OLLAS FLAG OLLAS 1D4 HA 1D4 HA 
ACKR3 0.0080 0.0001 0.9998 0.9995 0.9993 0.9988 0.9996 0.9993
ADCYAP1R1 0.0355 0.0001 0.9999 0.9997 0.0017 0.9868 0.1854 0.9994 
ADGRF5 0.0151 0.0001 0.9999 0.9998 0.7451 0.9988 0.9991 0.9997 
CALCR 0.0001 0.0001 0.9998 0.9853 0.2823 0.9947 0.8329 0.9993 
CALCRL 0.0001 0.0001 0.0001 0.0749 0.0001 0.0001 0.0001 0.0001 
CCR5 0.9994 0.9938 N/A N/A 0.9998 0.9999 N/A N/A 
CCR7 0.9993 0.4219 N/A N/A 0.9878 0.9999 N/A N/A 
CRHR1 0.2018 0.0001 0.9999 0.9999 0.9991 0.9998 0.9994 0.9998 
CRHR2 0.0221 0.0001 0.9993 0.9830 0.1470 0.9938 0.8527 0.7529 
CXCR3 0.8261 0.0015 N/A N/A 0.9997 N/A 0.9998 N/A 
CXCR4 0.9996 0.9991 N/A N/A 0.9999 N/A 0.9999 N/A 
GCGR 0.0001 0.0001 0.9999 0.9999 0.6740 0.9948 0.8946 0.9998 
GHRHR 0.0001 0.0001 0.9990 0.9992 0.0284 0.7504 0.2015 0.8697 
GIPR 0.0001 0.0001 0.9821 0.9991 0.0053 0.0290 0.1588 0.0120 
GLP1R 0.0001 0.0001 0.9853 0.8632 0.0722 0.2798 0.0539 0.5420 
GLP2R 0.0001 0.0001 0.9996 0.9991 0.0001 0.0290 0.0001 0.7387 
GPR182 N/A N/A 0.0001 0.0001 N/A 0.0001 N/A 0.0001 
GPR4 N/A N/A 0.0001 0.0001 N/A 0.0001 N/A 0.0001 
PTH1R 0.0001 0.0001 0.5993 0.6640 0.0001 0.1738 0.0001 0.0915 
PTH2R 0.0001 0.0001 0.2537 0.0302 0.0001 0.0162 0.0001 0.0531 
SCTR 0.0013 0.0001 0.9994 0.9952 0.0001 0.8881 0.0001 0.9936 
VIPR1 0.0001 0.0001 0.9996 0.8788 0.0015 0.8429 0.0544 0.9991 
VIPR2 0.0001 0.0001 0.9562 0.9378 0.0001 0.7792 0.0044 0.9685 
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We calculated an overall statistic for the significance of each GPCR-RAMP complex pair 
to combine the significances of interaction for each of the eight capture and detection pairs 
(Table 4-4). First, the statistical significances from the data presented in Figure 4-5 were 
calculated (Table 4-3). An ordinary one-way ANOVA, with Dunnett’s multiple comparison’s 
test was used to compare signal between mock transfected cell lysates and cell lysates 
cotransfected with each RAMP or GPCR construct. Resulting P-values of <0.0001 were assigned 
4, <0.001 a 3, <0.01 a 2, and <0.05 a 1. The values were summed and divided by the number of 
capture and detection pairs that we expected to be capable of measuring the relevant complex. 
For dual-tagged GPCRs, we divided by eight and for single-tagged GPCRs we divided by four to 
obtain a normalized value.  
73 
Table 4-4. Overall statistic for GPCR-RAMP complex formation. P-values are presented in 
Table 4-3. P-values <0.0001 were assigned 4, <0.001 a 3, <0.01 a 2, and <0.05 a 1. The values 
were summed and divided by the number of capture and detection pairs that we expected to be 
capable of measuring the relevant complex. For dual-tagged GPCRs, we divided by eight and for 
single-tagged GPCRs we divided by four to obtain a normalized value. Secretin-like receptors 
are shown in bold. * indicates that the complex formation was confirmed by PLA and † that 
complex formation was not confirmed by PLA (Figure 4-14). 
RAMP1 RAMP2 RAMP3 Previously published RAMP interaction 
ACKR3 0 1.125 0.75 Unknown 
ADCYAP1R1 1 0.75 0.75 Unknown 
ADGRF5 0.125 0.875 0.625 Unknown 
CALCR 0.25 1 1 RAMP1, 2 and 3 (41) 
CALCRL 4 4* 3.5 RAMP1, 2 and 3 (44, 45) 
CCR5 0 0 0 Unknown 
CCR7 0 0 0 Unknown 
CRHR1 0 0.625 0.375 RAMP2 (53, 55) 
CRHR2 0 0 0.75 None (53) 
CXCR3 0 0† 0.25 Unknown 
CXCR4 0 0 0 Unknown 
GCGR 0.625 1 2 Unknown 
GHRHR 0 2 1.125 RAMP2 (50, 51, 54) 
GIPR 1.125 2.375 1.125 None (54) 
GLP1R 1.75 1.875 1.25 None (50, 54, 55) 
GLP2R 2 2 2 None (54) 
GPR182 2.25 2.25* 4 Unknown 
GPR4 2.5 3.25* 4 Unknown 
PTH1R 2 2* 2.125 RAMP2 (54) 
PTH2R 2.25 2 2.125 RAMP3 (54) 
SCTR 1.625 2 1.75 RAMP3 (56) 
VIPR1 0 1.125 1.25 RAMP1, 2 and 3 (54) 
VIPR2 0.25 1.25 1.625 RAMP1, 2, and 3 (55) 
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4.3.4 Validation of Abs targeting RAMPs and GPCRs 
My next aim was to validate the SBA approach as a method to identify GPCR-RAMP 
interactions without having to rely upon the use of epitope tags engineered onto both the GPCR 
and the RAMP. Thus, I needed to assess the available protein-specific Abs to each GPCR and 
each RAMP, which were obtained from either commercial sources or HPA. In order to validate 
the utility of each anti-RAMP Ab, the cell lysates containing epitope-tagged RAMPs were 
incubated with the SBA, which included nine anti-RAMP Abs. The captured RAMPs were 
detected using the PE-conjugated OLLAS and PE-conjugated FLAG mAbs. I found that five out 
of the nine HPA and commercial anti-RAMP Abs (56%) selectively captured their intended 
RAMP. In addition, each anti-RAMP Ab showed little cross-reactivity with the other two non-
targeted RAMPs (Figure 4-6). Validated Abs are underlined in Table 4-2. 
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Figure 4-6. Validation of Abs used to capture RAMPs. In order to validate anti-RAMP Abs, 
lysates from cells transfected with each epitope-tagged RAMP construct (FLAG and OLLAS) 
were incubated with the SBA, which included beads conjugated with nine capture Abs targeting 
the three RAMPs. (A) PE-conjugated anti-FLAG and (B) PE-conjugated anti-OLLAS mAbs 
were used to detect any RAMPs captured by the beads. Data are median fluorescence intensity 
(MFI) and represent at least 200 experiments, each performed in duplicate. At a statistical 
significance of p£0.05 (Kruskal-Wallis ANOVA), we validated at least one capture Ab for each 
of the three RAMPs (a total of 5 RAMP capture Abs). Validated Abs are underlined. Bead ID 




In parallel, the collection of anti-GPCR Abs was validated for GPCR capture using cell 
lysates containing the 23 epitope-tagged GPCRs. In this case, the detection mAbs used were anti-
1D4 and anti-HA. When using either PE-conjugated anti-1D4 or PE-conjugated anti-HA as the 
detection mAb, 31 out of the 55 anti-GPCR Abs (~56%) tested captured their intended GPCR 
targets (Figure 4-7). Overall, I found that the anti-HA mAb was not as sensitive to detect GPCRs 
as the anti-1D4 detection mAb. To judge the ability of an Ab to capture its intended GPCR 
target, I used a Z-score cutoff of 1.645 (corresponding to the 95% confidence interval of a single-
tailed Z-test). I found that at least one HPA Ab for 19 of the 21 GPCRs (90%) included in this 
study, and with HPA Abs available, fulfilled the criteria (Table 4-2).  
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Figure 4-7. Validation of Abs used to capture GPCRs. In order to validate anti-GPCR Abs, 
lysates from cells transfected with each epitope-tagged GPCR construct (HA and/or 1D4) were 
incubated with the SBA, which included beads conjugated with 55 Abs targeting 21 GPCRs. (A) 
PE-conjugated anti-HA or (B) PE-conjugated anti-1D4 were used to detect any GPCRs captured 
by the beads. GPCRs are shown in alphabetical order and the labels in bold correspond to 
secretin-like GPCRs. Each dot in each bee-swam plot represents a data point from one 
experiment. The blue dots indicate signal from lysates containing the intended GPCR target, 
while grey dots indicate signal from lysates containing an of the other epitope-tagged GPCR 
targets. Data are median fluorescence intensity (MFI) and representative of at least 200 
experiments, each performed in duplicate. The occasional grey box indicates that the GPCR did 
not have the appropriate epitope tag to be captured or detected. At a statistical significance of 
p£0.05 we validated a total of 31 capture Abs, with at least one capture Ab for 19 of the 21 
GPCRs studied. Validated Abs are underlined. Bead ID numbers are listed after each GPCR 
name and the corresponding Ab name is provided in Table 4-2. 
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In addition to validating Abs with high affinity to their intended target, the SBA also 
gives information on the cross-reactivity of the Abs to the other GPCRs included in this study. I 
found that none of the validated Abs demonstrated cross-reactivity (Figure 4-8). 
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Figure 4-8. Analysis of anti-GPCR Ab cross-reactivity. Lysates from cells transfected with each 
epitope-tagged GPCR construct (HA and 1D4) were incubated with the SBA, which included 55 
Abs to 21 GPCRs. (A) PE-conjugated anti-1D4 and (B) PE-conjugated anti-HA were used to 
detect any GPCRs captured by the beads. The occasional grey boxes indicate that the GPCR did 
not have the appropriate epitope tag to be detected. The labels in bold correspond to secretin-like 
GPCRs and validated Abs are underlined. Heatmaps represent the z-scores of median 
fluorescence intensity (MFI) and indicates the ability of the GPCR Abs to capture each of the 23 
GPCRs used in the study. Data represents the median z-score of at least three experiments 
performed in duplicate. Bead ID numbers are listed after each GPCR name and the 
corresponding Ab name is provided in Table 4-2.  
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4.3.5 GPCR-RAMP complexes captured by validated anti-GPCR Abs 
Next, I explored the broader utility of using the anti-GPCR Abs to capture directly the 
GPCR-RAMP complexes. I examined the beads that were coupled to anti-GPCR Abs and 
measured signals arising from a bound RAMP using both PE-conjugated anti-FLAG and PE-
conjugated anti-OLLAS mAbs (Figure 4-9). In this experimental design, GPCRs can be captured 
through their native sequence, ablating the need to create epitope-tagged constructs. With few 
exceptions (<0.05%) the majority of signals associated with complex capture using the anti-
GPCR Abs that reached a Z-score ³ 1.645 were obtained from lysates containing the target 
GPCR.  
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Figure 4-9. Detection of GPCR-RAMP complexes following capture by anti-GPCR Abs. 
Lysates from cells transfected with each epitope-tagged RAMP construct (FLAG and OLLAS) 
and cotransfected with each epitope-tagged GPCR construct (HA and 1D4) were incubated with 
the SBA, which included 55 Abs to 21 GPCRs included in this study. Complexes were captured 
in multiplex fashion using the anti-GPCR Ab beads. The presence of a GPCR-RAMP complex 
was detected using (A) PE-conjugated OLLAS mAb, or (B) PE-conjugated anti-FLAG mAb. 
The labels in bold correspond to secretin-like GPCRs and validated Abs are underlined. The 
heatmap displays the Z-score of median fluorescence intensity (MFI) and represents at least three 
experiments performed in duplicate. Bead ID numbers are listed after each GPCR name and the 
corresponding Ab name is provided in Table 4-2.  
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4.3.6 Statistical comparison of SBA data sets 
I next determined whether the data obtained using anti-GPCR capture Abs recapitulated 
the results obtained with the epitope tag capture methods. I first converted the anti-GPCR data 
set (Figure 4-9) to a binary (0,1) matrix by using a Z-score threshold set to 1.645, which 
corresponds to a confidence interval of 95%, for a single-tailed test. I then created a hypothetical 
matrix of results based on the data set obtained from using epitope tags to capture GPCR-RAMP 
complexes and the overall statistic for GPCR-RAMP interaction from Table 4-4. For example, 
the two anti-CALCRL antibodies were assigned a 4 for interaction with RAMP1, RAMP2 and a 
3.5 with RAMP3 but only with lysates coexpressing CALCRL and each RAMP (Figure 4-10).  
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Figure 4-10. Hypothetical matrix of results for RAMP-GPCR heterocomplexes captured by 
GPCR Abs based on data from epitope tag capture and detection. Lysates from cells transfected 
with each epitope-tagged RAMP construct (FLAG and OLLAS) and cotransfected with each 
epitope-tagged GPCR construct (HA and 1D4) were incubated with the SBA, which included 
mAbs to the four engineered epitope tags. Complexes were captured in multiplex fashion using 
one of the four mAbs, with eight possible capture-detection schemes. An overall statistic for 
GPCR-RAMP complex formation was calculated by assigning P-values derived from Figure 4-5 
of p <0.0001 a 4, p <0.001 a 3, p <0.01 a 2, and p <0.05 a 1 for each capture-detection mAb pair 
(Table 4-3 and Table 4-4). The values were summed and divided by the number of capture and 
detection pairs that we expected to be capable of measuring the relevant complex. The labels in 
bold correspond to secretin-like GPCRs. Heatmap represents the overall statistic and is the 
hypothetical expected data for Figure 4-9.  
The threshold used to convert the epitope tag data to binary form was increased by an 
interval of 0.125 and then the following metrics were plotted: (a) overall percent agreement (P0), 
(b) the percent of hits from the epitope tag data that are also found in the anti-GPCR Ab data 
(sensitivity), (c) the percent of non-hits from the epitope tag data that are also non-hits in the 
 88 
anti-GPCR Ab data (specificity), (d) the probability of a positive result in the anti-GPCR Ab data 
also being a positive in the epitope tag data (positive predictive value), (e) the probability of a 
negative result in the anti-GPCR Ab data also being a negative in the epitope tag data (negative 
predictive value) and (6) the similarity of the two data sets (Jaccard Index) (Table 2-2). 
Overall, using anti-GPCR Abs to capture GPCR-RAMP complexes results in data that 
corroborates with the results from using epitope tag mAbs (Figure 4-11). The overall agreement, 
specificity, and negative predictive value reach nearly 100% at the lowest threshold used to 
create a binary matrix from the anti-epitope tag capture data. The high correspondence for these 
metrics agrees with the observation that the majority of signals from GPCR Abs that reach a Z-
score of 1.645 are seen only with lysates containing the intended GPCR target. The ability of 
anti-GPCR Abs to successfully capture the heterocomplexes is represented by the sensitivity, 
positive predictive value, and Jaccard index. All in three metrics, the OLLAS detection mAb 
performed better than the FLAG detection mAb. Unsurprisingly, the validated GPCR Abs 
demonstrated more congruency of positive results between the datasets. The Jaccard index 
represents the overall agreement of the positive results in both data sets and indicates at which 
threshold the agreement is maximized. The threshold that maximizes the agreement between the 
data sets was 1.125 in the case of both OLLAS and FLAG detection, and with all GPCR Abs and 
the validated GPCR Abs. However, the Jaccard index is only minimally smaller even at the 
lowest threshold (0.125), with a difference of 2-10%. In all, the population of false negatives 
arising from the anti-GPCR Ab data is very small. When using an OLLAS detection mAb and 




Figure 4-11. Statistical validation of GPCR-RAMP SBA data sets. Data obtained from the 
capture of the GPCR-RAMP complexes using anti-epitope mAbs (Figure 4-5) were compared 
with data obtained from the GPCR-RAMP complexes captured using anti-GPCR Abs (figure 4-
9). PE-conjugated anti-FLAG was used to detect GPCR-RAMP complexes captured using (A) 
all anti-GPCR Abs or (B) validated anti-GPCR Abs. Alternatively, PE-conjugated anti-OLLAS 
mAb was used to detect GPCR-RAMP complexes captured using (C) all anti-GPCR Abs or (D) 
validated anti-GPCR Abs. The Z-score threshold for the anti-GPCR Ab data was set at 1.645. P0 
(blue), positive predictive value (green), negative predictive value (red), sensitivity (yellow), 
specificity (grey), and Jaccard Index (black) are plotted as a function of increasing threshold for 
the interaction results using epitope tags for capture and detection (Table 4-4). Table 2-2 shows 
the formulas and metrics used and provides a narrative description of each of the statistical 
terms. For example, the Jaccard Index represents the overall agreement of the positive results in 
both data sets and indicates at which threshold the agreement is maximized. 
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4.3.7 Summary of RAMP-GPCR complexes detected using an SBA assay 
I used several detection and capture Ab pairs in a multiplexed fashion to identify GPCR-
RAMP complexes. The complexes were captured through epitope tags engineered onto the 
GPCR or RAMP, and PE-conjugated anti-epitope tag mAbs were used to detect the putative 
interacting partner. In this experimental setup there were eight combinations of capture/detection 
pairs to identify complexes of dual-epitope tagged GPCRs with RAMPs, or four 
capture/detection pairs to identify complexes of single-epitope-tagged constructs. In addition, 
many of the Abs validated to capture the GPCRs or RAMPs also captured the GPCR-RAMP 
complexes. These data were collected in multiplexed fashion. A summary of the results obtained 
from all of the combinations of capture/detection Ab pairs employed are presented graphically in 
Figure 4-12. Generally, the GPCRs that exhibit complex formation with RAMPs either form 
complexes with all three RAMPs, or RAMP2 and RAMP3.  
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Figure 4-12. Graphical summary of GPCR-RAMP complexes detected using an SBA assay. 
Each circle depicts a unique GPCR along with each of the three RAMPs. Each GPCR is labeled 
and color coded. RAMP1 is colored grey, RAMP2 is colored lime, RAMP3 is colored tangerine. 
Curved lines within the circles show GPCR-RAMP interactions, and the thicknesses of the lines 
shows relative statistical significance (see below). The small labels around the circumference 
indicate the Abs used for the SBA experiments. In total four anti-epitope tag mAbs, 31 validated 
Abs to the 23 GPCRs included in the study, and five validated Abs to the three RAMPs are 
shown. Three GPCRs tested (CCR5, CCR7 and CXCR4) did not form complexes with RAMPs 
and are not shown here. The statistical significance derived for the particular interaction using 
the indicated capture/detection pair is represented by the thickness of the curved lines. P values 
of p £ 0.05 are given an arbitrary thickness of 1, p £ 0.01 a thickness of 2, p £ 0.001 a thickness 
of 3, and p £ 0.0001 a thickness of 4. Bead ID numbers are listed with each GPCR name and the 
corresponding validated Ab names are provided in Table 4-2. 
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4.4 Validation of GPCR-RAMP interactions by PLA 
In order to show the presence of selected GPCR-RAMP complexes in membranes, we 
employed a proximity ligation assay (PLA). The PLA method enables detection of protein 
interactions, which are visualized as fluorescent puncta (112). In principle, each PLA punctum 
corresponds to a single protein-protein complex that reacts with two primary Abs, one per 
protein. The distance constraints for PLA proximity detection are fairly stringent and the 
fluorescence signal is highly amplified using a rolling circle DNA polymerization that hybridizes 
with fluorescent complementary oligonucleotides. The PLA can be carried out in situ in a cell 
membrane environment, which provides evidence for the functional relevance of the SBA 
results.   
4.4.1 Establishment of the PLA method to detect GPCR-RAMP complexes 
To detect the extracellular epitopes, we employed anti-HA and anti-FLAG Abs for 
CALCRL and RAMP2, respectively. Following PLA processing, we used a DAPI stain to 
visualize the cell nucleus and to count cells. Images were taken in the blue channel to visualize 
the cell nucleus and red channel to identify PLA puncta (Figure 4-13A). Omitting either the anti-
HA or anti-FLAG primary Abs during PLA processing of CALCRL and RAMP2 cotransfected 
cells measured primary Ab nonspecific binding, while omitting all primary Abs measures 
nonspecific binding of the PLA probes. Mock transfected cells treated with both Abs served as a 
negative control (Figure 4-13B). PLA puncta count from cells that were cotransfected with 
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CALCRL and RAMP2 and incubated with both primary Abs were significantly higher compared 
to control treatments and mock transfected cells (Figure 4-13C).  
Next, we determined whether the puncta count from the CALCRL and RAMP2 
cotransfected cells were localized to the cell membrane since misfolded protein can accumulate 
in the endoplasmic reticulum. The accumulation of misfolded protein in the endoplasmic 
reticulum could cause the PLA method to appear to detect false positive protein-protein 
interactions. Puncta count from RAMP2 and CALCRL cotransfected cells were compared when 
using a permeabilizing fixation reagent, methanol, and a non-permeabilizing fixation reagent, 
formaldehyde (FA). There was no significant difference between puncta count using the two 
different fixation reagents (Figure 4-13D).  
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Figure 4-13. Detection of CALCRL-RAMP2 interactions in cell membranes using PLA. Cells 
were cotransfected with epitope-tagged GPCR and RAMP2 then incubated with a-HA and a-
FLAG Abs. PLA was then carried out to quantitate GPCR-RAMP2 interactions. The number of 
PLA puncta per cell for each Z-stack captured was measured. Each Z-stack is of a different field 
of view. (A) Representative PLA images showing greyscale split-channel view of a Z-stack 
maximum projection for cells cotransfected with CALCRL and RAMP2 and treated with both 
primary Abs. The merge is presented in color. Scale bars, 5µm for both (A) and (C). Blue = 
DAPI, red = PLA puncta. (B) Representative images of PLA performed on CALCRL and 
RAMP2 cotransfected cells with Ab incubation detection as noted. Images show maximum 
projection of Z-stack, which is the maximum signal intensity for each channel at each point 
across all slices in the Z-stack. (C) Quantitation of control PLA experiments performed on 
CALCRL and RAMP2 cotransfected cells. PLA puncta counts were compared between samples 
that received both primary Abs and samples that received only anti-HA Ab, only anti-FLAG Ab, 
no primary Abs, or mock transfection with both primary Abs. Data are from two experiments 
performed with at least three replicates. (D) PLA puncta counts per cell for cells cotransfected 
with CALCRL and RAMP2, fixed with either FA or methanol and subjected to PLA. Data are 
from at least two experiments performed with at least five replicates. Significance determined by 
two-tailed P-test. Scale bars, 5µm. Blue = DAPI, red = PLA puncta. 
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4.4.2 Validation of RAMP-GPCR interactions using the PLA method. 
We next used PLA to test GPCR-RAMP2 interactions in cell membranes for a variety of 
other GPCRs that were also studied using the SBA method. We focused on quantifying 
interactions between RAMP2 and CALCRL, PTH1R, GPR182, GPR4 and CXCR3 (Figure 4-
14A). These GPCRs showed a range of capabilities to interact with RAMP2 in the SBA under 
conditions of detergent solubilization. Puncta were quantified over multiple Z-stacks, creating a 
3D image of puncta (Figure 4-14B). The PLA results indicated that there were differences in 
puncta count among the receptor-RAMP2 pairs studied. Overall, the results of the PLA on a 
limited number of GPCR-RAMP pairs were consistent with the results of the SBA. 
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Figure 4-14. Validation of GPCR-RAMP complex formation in cell membranes using PLA.  
Cells were cotransfected with epitope-tagged GPCR and RAMP2 then incubated with a-HA and 
a-FLAG Abs. PLA was then carried out to quantitate GPCR-RAMP2 interactions. The number 
of PLA puncta per cell for each Z-stack captured was measured. Each Z-stack is of a different 
field of view. (A) PLA puncta counts for cells cotransfected with RAMP2 and selected GPCRs. 
Data are from at least three experiments performed with at least five replicates. (B) 
Representative images of cells cotransfected with RAMP2 and selected GPCRs and subjected to 
PLA. Top row shows maximum projection of Z-stack, which is the maximum signal intensity for 
each channel at each point across all slices in the Z-stack. The bottom row shows snapshots from 
puncta quantification performed in Imaris. Scale bars, 5µm top row, 8µm bottom row. Blue = 
DAPI, red = PLA puncta, grey = Imaris spots. The statistical test for significance used was a 
one-way ANOVA followed by Dunnett’s multiple comparisons test (****P<0.0001, NS = not 
significant). 
4.5 Discussion 
We present a novel method to detect interactions between GPCRs and RAMPs that may 
have general utility to detect interacting partners of membrane proteins more broadly. The 
method relies on the preparation and validation of Abs for a suspension bead-based assay, which 
allows multiplexed immunocapture and detection of a large number of discrete proteins from a 
lysate mixture. The SBA we developed contains uniquely bar-coded beads conjugated to four 
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mAbs against epitope tags engineered at the N- and C-terminal tails of the expressed GPCRs and 
RAMPs, nine Abs against three different RAMPs, 55 Abs against 21 of the 23 GPCRs studied, 
and control beads. Captured GPCRs, RAMPs, or GPCR-RAMP complexes were detected by 
mAbs against the engineered epitope tags. In a single multiplexed experiment, we could use a 
variety of capture and detection strategies to identify complexes. The complexes were captured 
using the epitope tags on the GPCRs and detected using the epitope tags on the RAMPs, and vice 
versa. Finally, GPCR-RAMPcomplexes were captured by protein-specific Abs, demonstrating 
the possibility to detect these complexes without the need for protein engineering to introduce 
the epitope tags. We found that the results obtained using validated anti-GPCR or anti-RAMP 
Abs were concordant to those obtained using the anti-epitope tag mAbs for complex capture.  
Using the SBA assay strategy, we identified previously reported secretin-like GPCR-
RAMP complexes. For example, we show that CALCRL forms stable complexes with each of 
the three RAMPs, which have been well characterized in the literature (111). In addition, we also 
detected and confirmed the formation of other complexes between secretin-like GPCRs and 
RAMPs that have been previously reported: CALCR with all three RAMPs, CRHR1 with 
RAMP2, GCGR with RAMP2, PTH1R with RAMP2, PTH2R with RAMP3, SCTR with 
RAMP3, VIPR1 with RAMP2 and RAMP3, and VIPR2 with all three RAMPs (44, 45, 50, 51, 
54–56). However, we failed to observe one previously reported complex, VIPR1 with RAMP1. 
The presence of a putative VIPR1-RAMP1 complex was inferred earlier because the cell surface 
expression of RAMP1 increased upon coexpression of VIPR1 (54). The majority of the GPCR-
RAMP interactions reported earlier were also based upon reciprocal effects of heterologous 
overexpression, and to our current knowledge, not on any type of direct binding assay. Many of 
the GPCR-RAMP interactions had remained unverified by other experimental methods. Our 
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findings using the SBA assay system to capture and detect actual GPCR-RAMP complexes 
appear to validate most of the earlier indirect findings. The results also validate the Abs and 
assay procedure as a robust method to detect and quantitate the presence of GPCR-RAMP 
complexes from cell lysates.  
In addition, we discovered several new secretin-like GPCR-RAMP complexes that have 
not been described previously. We found that GIPR and ADCYAP1R1 formed complexes with 
all three RAMPs. To our knowledge, GIPR and ADCYAP1R1 have not been studied earlier with 
respect to their ability to interact with RAMPs. In addition, we found that several secretin-like 
GPCRs that were previously reported to not interact with RAMPs did indeed form complexes 
that were detected in the SBA assay. In particular, both GLP1R and GLP2R demonstrated 
complex formation with all three RAMPs, and GHRHR formed a complex with RAMP2 and 
RAMP3, but not with RAMP1. CRHR2 showed a very low probability of complex formation 
with RAMP3, but not with RAMP1 and RAMP2. These receptors had been judged not to form 
complexes with RAMPs because overexpression of the receptors in HEK293 or COS-7 cells did 
not cause coexpressed RAMPs to translocate to the cell surface (53, 54). Our results show 
directly the existence of GPCR-RAMP complexes and suggests that RAMP translocation studies 
may not be sensitive to detect all GPCR-RAMP interactions (113). The method we present 
detects interactions occurring anywhere in the cells, as opposed to just the cell membrane. Of 
note, preliminary data from another report did suggest that RAMPs were detected at the cell 
surface when coexpressed with GLP2R in HEK293T cells (114).  
Interactions between RAMPs and GPCRs beyond the secretin-like family have remained 
largely unexplored, with the exception of GPER30 and CaSR (9, 57, 58). Here, among the few 
non-secretin-like receptors targeted by our SBA, we discovered interactions of RAMPs with 
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chemokine receptors and orphan receptors. The orphan receptors GPR4 and GPR182 interacted 
with all three RAMPs. Intriguingly, GPR4 demonstrates cell-type selectivity in response to 
lysolipids, potentially a result of differential RAMP expression in different cell types (115). The 
chemokine receptors ACKR3/CXCR7 and CXCR3 also interacted weakly with RAMP2 and 
RAMP3. 
Notably, two of the GPCRs that were demonstrated to interact with RAMP2 and RAMP3 
have been linked to ligands targeting CALCRL in complex with one of the three RAMPs. These 
GPCRS, ACKR3/CXCR7 and GPR182, have not been previously reported to interact with 
RAMPs. GPR182 has been reported to be a receptor for adrenomedullin, a peptide ligand that 
signals through the CALCRL/RAMP2 complex (116). GPR182 was reclassified as an orphan 
receptor when these results could not be reproduced (117). ACKR3/CXCR7, a chemokine 
receptor, was originally described as a receptor for both adrenomedullin and calcitonin-gene 
related (CGRP), a peptide ligand that signals through the CALCRL/RAMP1 complex (118). 
More recently, ACKR3/CXCR7 was demonstrated to act as decoy receptor for adrenomedullin 
(79). This opens up the possibility that RAMPs can facilitate adrenomedullin or CGRP binding 
to these receptors.  
Results obtained using mAbs to capture and detect RAMP-GPCR complexes through 
epitope tags showed variation among the different combinations of detection and capture Abs. 
For example, using OLLAS and 1D4 mAbs as the capture-detection pair was generally more 
sensitive than using HA and FLAG mAbs.  Of note, the well-validated interaction between 
CALCR and each of the RAMPs was only detected by several, but not all mAb capture-detection 
pairs. Of course, the main reason for the variation in signal sensitivity among the different mAb 
pairs employed could be related to differences in Ab affinity and sensitivity. In line with this 
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hypothesis, the anti-OLLAS mAb has been demonstrated to have at least 100-fold higher affinity 
than anti-FLAG mAbs (107).  
Recent structural studies provide insight into the potential role of GPCR-RAMP complex 
formation. A cryogenic electron microscopy structure of the CALCRL-RAMP1 complex shows 
that RAMP1 forms extensive contacts with transmembrane helices 3, 4 and 5 as well as with 
extracellular loop 2 (ECL2) of CALCRL (49). The agonist ligand of CALCRL-RAMP1 makes 
contacts with the with ECL2 of CALCRL. In contrast, there are very minimal direct contacts 
between the ligand and RAMP1, suggesting that the complex should exist in the absence of 
ligand (48). The extensive contact surface between CALCRL and RAMP1 suggests that the 
complex should be stable under conditions used here in the SBA assay. Given that the CALCRL-
RAMP1 structure is generalizable to other possible GPCR-RAMP complexes, Abs that would 
capture the GPCR through ECL2 might fail to recognize the same GPCR in complex with a 
RAMP. In line with this hypothesis, we found that a subset of validated anti-GPCR Abs were 
unable to capture a GPCR-RAMP complex that were identified through capture using other anti-
GPCR Abs or anti-epitope tag mAbs.   
We validated a set of Abs to detect GPCR-RAMP complexes in order to avoid artifacts 
inherent in having to rely upon insufficiently characterized Abs (119, 120). Cross-reactivity of 
anti-GPCR Abs is a particular problem due to structural and amino acid sequence similarity 
among GPCRs (24). The multiplexed nature of the SBA assay allowed us to both validate Abs to 
the RAMPs and GPCRs and check for potential cross-reactivity and off-target binding to all 
other GPCRs included in the study. We assessed Ab cross-reactivity even in the absence of the 
intended GPCR while unintended GPCR targets were overexpressed. Using the SBA, we found 
at least one Ab that targeted the intended GPCR with high selectivity for 19 of the 21 targets 
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with HPA Abs available. We also found at least one Ab to each RAMP that specifically captured 
the targeted RAMP. Future experiments will validate additional anti-GPCR Abs as they become 
available. In addition, the SBA strategy can be used to screen for therapeutic mAbs that show the 
lowest cross-reactivity with other GPCRs.  
By being able to use protein-specific, anti-GPCR Abs in the multiplexed SBA assay, the 
requirement to use engineered epitope tags and a heterologous overexpression system would be 
eliminated. This would alleviate the potential of identifying non-physiological interactions, since 
the requirement for overexpressing both proteins would be removed. Thus, we determined 
whether anti-GPCR Abs can capture the GPCR-RAMP complexes directly. The pre-validated 
anti-GPCR Abs used in the SBA were able to capture the majority of the GPCR-RAMP 
complexes as demonstrated by using OLLAS mAb detection.  
In order to show the presence of selected GPCR-RAMP complexes in membranes, we 
used PLA, which is an immunolocalization assay in which the proximity of two different Abs is 
detected using oligonucleotide-labeled secondary Abs. The PLA can be carried out in situ in a 
cell membrane environment, which provides evidence for the functional relevance of the SBA 
results. While PLA has been used to detect GPCR heteromers (121), to our knowledge there 
have been no reports on its use to detect GPCR-RAMP complexes. Cells cotransfected with 
CALCRL and RAMP2 and treated with both primary Abs showed a significant PLA signal in 
comparison to all the negative controls, indicating that the assay is robust. We also compared 
results from the PLA using methanol-fixed cells to those using FA-fixed cells. The difference 
between the methanol and FA data sets was not significant, ensuring that most of the signal came 
from protein complexes on the membrane.  
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Although transient protein overexpression by cotransfection is subject to experimental 
variation, PLA puncta can be quantified, which together allows a semi-quantitative assessment of 
the extent of GPCR-RAMP interactions within the cellular context. We used the PLA to test a 
subset of GPCRs (PTH1R, GPR4, GPR182, and CXCR3) that were shown to interact with 
RAMP2 in the SBA assay. However, the CXCR3-RAMP2 interaction was detected only with 
one capture Ab at a low statistical significance. In concordance with the SBA results trend, we 
confirmed complex formation between RAMP2 and the PTH1R, GPR4 and GPR182, but the 
signal for CXCR3 did not meet statistical significance. Therefore, the PLA results highlight the 
importance of confirming the SBA results by a complementary method, especially when a 
RAMP-GPCR complex was observed with only one capture Ab.  
In summary, the multiplexed SBA assay we developed enables the validation and use of 
Abs for the detection of GPCR-RAMP interactions. As a proof-of-concept, we defined the 
complete interactome between secretin-family GPCRs and RAMPs (Fig. 4). We also identified a 
number of novel GPCR-RAMP interactions, including some interacting partners among 
rhodopsin-family GPCRs that we selected for study based on earlier bioinformatics analysis. We 
used the in situ PLA to verify the extent of the interaction between several GPCR-RAMP2 pairs 
tested in the SBA. The SBA is scalable, allowing up to 500 beads to be conjugated with different 
Abs and decoded in the Luminex system. Therefore, we intend to expand the existing SBA, 
which consisted of 70 beads, based on the validation of additional Abs using epitope-tagged 
controls. We also look forward to using the SBA strategy to study other protein-protein 
interactions, including, but not limited to, GPCR heterodimerization. We consider the SBA 
technology to be potentially transformative with respect to studies of membrane protein systems. 
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CHAPTER 5. Future Perspectives 
5.1 Additional computational methods for validating and predicting GPCR-protein 
interactions 
We used two computational approaches to demonstrate that interactions between GPCRs 
and RAMPs are likely widespread – coexpression and coevolution. There are additional 
computational methods for predicting protein-protein interactions (PPIs) that were not used here. 
For example, machine learning algorithms to predict PPIs can find features shared among protein 
pairs with known interaction but not seen in non-interactors. Once the common features of a 
particular protein-protein complex are determined, the algorithm can classify new protein pairs 
as interactors or non-interactors (122). Information obtained about GPCRs that interact with 
RAMPs from the SBA assay will allow the implementation of machine learning to find 
additional GPCRs likely to interact with RAMPs.  
Another computational method to predict new PPIs is homology modeling, which 
requires a well-resolved three-dimensional structure as a reference structure. Recently, a new 
publication has described a CALCRL-RAMP1 structure at 3.3 Å resolution (49). This structure 
will assist in the prediction of new GPCR-RAMP interactions, validation of experimentally 
determined interactions and elucidation of the molecular mechanisms of GPCR specificity for 
RAMPs. The power of homology modeling has been highlighted in a study regarding RAMP 
interactions with CRHR1 and CRHR2. CRHR2 does not interact with RAMP2, while the closely 
related CRHR1 does interact with RAMP2. Homology modeling of the ectodomains revealed 
that in CRHR1, two negatively charged residues are attracted to a histidine in RAMP2. But in 
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CRHR2, one of the corresponding residue is histidine, causing electrostatic repulsion away from 
RAMP2 (53). Also, of note, I found that RAMP2 and RAMP3 show very similar coexpression 
patterns with GPCRs and form complexes with the same GPCRs. Thus, a specific component 
found in RAMP2 and RAMP3, but not RAMP1, may contribute to GPCR specificity. 
Interestingly, RAMP1 and RAMP3 show more general structural similarity at the extracellular 
region, with a shorter N-terminal tail than RAMP3. However, both RAMP2 and RAMP3 are 
glycosylated and contain glutamic acid at position 74. In RAMP1, the corresponding residue is 
tryptophan, which is an essential residue in conferring antagonist specificity (123). In addition, 
the role of the transmembrane region of RAMP has yet to be investigated for its potential role in 
conferring GPCR-interaction specificity. These features may contribute to receptor specificity 
and warrant further analysis.  
5.2 Scaling up the SBA method for high-throughput GPCR-protein interaction assay 
To our knowledge, no robust proteomics approaches are available to address GPCR-
protein interactions. GPCRs are underrepresented in mass spectrometry data, in part due to the 
lack of efficient proteolysis procedures (86). Affinity assays to screen for GPCR-protein 
interactions, or membrane protein-protein interactions in general, have been lacking due to 
difficulties in (i) generating Abs that are functional in the intended assay system (24, 124) and 
(ii) extracting GPCRs from the native environment while maintaining both their binding 
capabilities and their accessibility for Ab-based detection. Using the SBA assay system, we 
validated at least one Ab from the HPA Ab library for 19 GPCRs. We were unable to validate 
Abs for only two of the GPCRs tested. It is feasible that a far more complete set of GPCRs can 
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be captured by an SBA-based assay once additional GPCR Abs are investigated. It is important 
to note that many additional anti-GPCR Abs, validated by other immunoassays, became 
available from HPA following the performance of the experiments described here. Also, we plan 
to investigate Abs from other commercial sources to identify and validate a complete set of 
useful anti-GPCR Abs.  
Once a complete set of anti-GPCR Abs has been identified, the SBA method can be used 
to investigate additional GPCR-RAMP as well as other GPCR-protein interactions. One of the 
potential pitfalls in identifying GPCR-RAMP interactions is the need to overexpress both the 
GPCR and RAMP in a heterologous system, which can inadvertently drive non-physiological 
complex formation by mass action. Thus, we were interested in determining if the SBA method 
has the potential to detect GPCR-RAMP interactions of endogenously expressed GPCRs. To 
detect GPCR interactions from cells endogenously expressing GPCRs, anti-GPCR Abs must be 
able to capture the complex. Here, I showed that protein-specific anti-GPCR Abs were capable 
of capturing the majority of RAMP-GPCRs interactions identified (Figure 4-9). These 
experiments still required the use of engineered epitope tags on the RAMP proteins for detection 
of the GPCR-RAMP complex. To detect endogenous interactions, GPCR-RAMP complexes 
should be able to be captured using anti-GPCR Abs and detected using anti-RAMP Abs, thus 
alleviating the need for epitope tags on either protein. I found that CALCRL-RAMP2 and 
CALCRL-RAMP3 complexes could be detected without the need for epitope tags (Figure 5-1). 
However, these experiments were performed on lysates overexpressing both the GPCR and 
RAMP. Thus, we will use next determine if we can capture endogenous GPCR-RAMP 
interactions by investigating lysates from cell lines and tissues that are known to endogenously 
express a RAMP and CALCRL, such as the SK-N-MC cell line and human lung tissue. For an 
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endogenous GPCR-RAMP interaction experiment, lysates of interest will be incubated with an 
SBA containing Abs to GPCRs expressed in the lysate and GPCR-RAMP interactions will be 
detected with a PE-conjugated anti-RAMP Ab. It is possible that a GPCR-interacting protein of 
interest does not have a well-validated, protein-specific Ab. In this case, heterologous expression 
of an epitope-tagged putative GPCR-interacting protein can be used to identify interactions. 
Even in this case, the requirement for heterologous expression of the hundreds of GPCRs can be 
avoided by using cell lines or tissues that endogenously express GPCRs of interest. 
Figure 5-1. Capture and detection of CALCRL-RAMP complexes using protein-specific 
Abs.Lysates from cells transfected with mock (black), the indicated RAMP alone (light grey), or 
cotransfected with CALCRL and the indicated RAMP (dark grey) were incubated with the SBA, 
which included beads conjugated to a validated Ab targeting CALCRL. The GPCR was captured 
using anti-CALCRL Ab and the CALCRL-RAMP complex is detected using (A) PE-conjugated 
anti-RAMP2 Ab or (B) PE-conjugated anti-RAMP3 Ab. Data are median fluorescence intensity 




















































I demonstrated the capability of the SBA method, especially in combination with 
bioinformatics, to identify global GPCR-RAMP interactions. However, the approaches I 
demonstrated are not limited to the study of GPCR-RAMP interactions. Both the SBA method, 
as well as the bioinformatics approach, may be extended to other single transmembrane proteins 
that interact with GPCRs, including receptor transporting proteins (RTPs), receptor expression 
enhancing proteins (REEPs), melanocortin receptor accessory proteins (MRAP), and the M10 
major histocompatbility proteins (MHC). An SBA could also be utilized to identify stable 
transmembrane interactions of GPCR heterocomplexes. Such experiments using the SBA 
method can elucidate a map of GPCR-transmembrane interactions, which is vital for 
understanding the full regulation of GPCRs (125, 126).  
Finally, the SBA strategy can also be used to screen for therapeutic anti-GPCR mAbs 
with low cross-reactivity to other GPCRs. MAbs targeting GPCRs are of increasing interest as 
therapeutic agents (24). However, GPCR Abs suffer from cross-reactivity due to high amino acid 
sequence homology among closely related GPCRs. To screen putative therapeutic mAbs, the 
anti-GPCR mAbs could be coupled to unique beads as capture mAbs to create an SBA. Then 
lysates containing an epitope-tagged GPCR of interest, as well as closely related GPCRs, could 
be incubated with the SBA and anti-epitope mAbs targeting the GPCR would be used for 
detection. Highly specific capture mAbs would show signal only with the lysate containing the 
tagged GPCR of interest and could thus be identified for further development.     
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5.3 Implications of RAMP interactions with additional GPCRs 
Since GPCRs participate in numerous molecular processes and are targeted by ~40% of 
pharmaceuticals, mapping GPCR interactions with RAMPs has important implications for both 
basic biology as well as translational medicine (127). For example, nearly 30% of non-olfactory 
GPCRs remain orphan receptors, whose endogenous ligands are unknown. Despite evidence that 
orphan receptors are important in many pathophysiological states, the rate of GPCR de-
orphanization has decreased drastically in the last few decades (128). We found that RAMPs 
interacted with orphan GPCRs GPR4 and GPR182 and observed that RAMPs are globally 
coevolved and coexpressed with GPCRs. Since the discovery of RAMPs led to the de-
orphanization of CALCRL, it is feasible to expect that the identification of novel orphan GPCR-
RAMP interactions would bolster the field of GPCR deorphanization.  
A particularly compelling orphan GPCR we found to interact with RAMPs is GPR182. 
As mentioned previously, GPR182 was once thought to be the receptor for adrenomedullin. 
Adrenomedullin is now known to signal through the CALCRL-RAMP2 or CALCRL-RAMP3 
complex. It is possible that a RAMP interaction is required for GPR182 to respond to 
adrenomedullin. We plan to investigate the modulation of GPR182 activity by RAMP2 and 
RAMP3. We will use an ERK phosphorylation assay since it is currently unclear which G 
protein subtype is activated by GPR182 and ERK phosphorylation involves signaling 
components downstream of each Ga protein subtypes and b-arrestin (11).  Supporting the use of 
an ERK phosphorylation assay, GPR182 acts as a negative regulator of ERK phosphorylation 
(129).   
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In addition, RAMPs may provide new opportunities for drug development. Currently, the 
only FDA-approved drug that targets a GPCR-RAMP complex is erenumab, a mAb which 
inhibits CGRP signaling through CALCRL-RAMP1 (130, 131). The identification of new 
GPCR-RAMP interactions will help guide GPCR-focused drug development (132). One 
possibility in RAMP-focused drug discovery is to develop bitopic ligands that target a RAMP 
and interacting GPCR. By targeting both proteins, bitopic ligands are likely to have increased 
specificity to the GPCR or GPCR-RAMP complex and can be used to target a GPCR in 
particular tissue(s) that coexpress a specific RAMP and GPCR (133).  
New GPCR-RAMP interactions have the potential to address a significant problem in 
translational biology - the failure of preclinical model systems to predict drug success (127). 
Since RAMPs can dramatically modulate the ligand-binding affinity and activity of a GPCR, the 
presence or absence of a RAMP in the model system could alter the potency or activity of a drug. 
When investigating a drug targeting a RAMP-interacting GPCR, an appropriate model system 
would need to express the same RAMP(s) that are expressed in the intended target tissues. 
Several of the GPCRs determined to interact with RAMPs by the SBA experiments have 
investigational drug candidates in either preclinical development or clinical trials (22). 
Given that GPCR signaling is an essential process in nearly every physiological aspect of 
human cells, the need for a detailed GPCR-RAMP interactome map is necessary. Ideally, a full 
map would detail which GPCR interacts with which RAMP and would provide information 
about the corresponding molecular impact, including changes in GPCR ligand specificity, 
trafficking and signaling. Our work to develop a robust multiplexed assay used to determine the 
secretin-like GPCR-RAMP interactome provides a first step toward that goal.   
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APPENDIX A: G Protein Subtype-specific Signaling Bias in a Series of CCR5 Chemokine 
Analogs 
A.1 Abstract 
Chemokines and some chemical analogs of chemokines prevent cellular HIV-1 entry 
when bound to the HIV-1 coreceptors C-C chemokine receptor 5 (CCR5) or C-X-C chemokine 
receptor 4 (CXCR4), which are G protein-coupled receptors (GPCRs).  The ideal HIV-1 entry 
blocker targeting the coreceptors would display ligand bias and avoid activating G protein-
mediated pathways that lead to inflammation. We compared CCR5-dependent activation of 
second messenger pathways in a single cell line. We studied two endogenous chemokines 
[RANTES (also known as CCL5) and MIP-1α (also known as CCL3)] and four chemokine 
analogs of RANTES (5P12-, 5P14-, 6P4- and PSC-RANTES).  We found that CCR5 signaled 
through both Gi/o   and Gq/11.  IP1 accumulation and Ca2+ flux arose from Gq/11 activation, rather 
than from Gβγ subunit release after Gi/o activation as had been previously proposed.  The 6P4 
and PSC RANTES analogs were superagonists for Gq/11 activation, whereas the 5P12 and 5P14 
RANTES analogs displayed a signaling bias for Gi/o. These results demonstrate that RANTES 
analogs elicit G protein subtype-specific signaling bias and can cause CCR5 to couple 
preferentially to Gi/o rather than Gq/11 signaling pathways.  We propose that G protein subtype-




Canonically, GPCR signaling involves sequential activation of a single type of Gα 
protein class followed by β-arrestin-dependent activation of non-canonical signal pathways. 
According to the concept of functional selectivity or ligand bias, signaling intensity can be 
skewed toward either the G protein pathway or the β-arrestin pathway (12, 134). Biased ligands 
are potentially desirable therapeutic agents that modulate specific signaling pathways relevant to 
disease processes (135). However, designing biased ligands requires a thorough understanding of 
receptor pharmacology and the appropriate cell-based assay systems to characterize the 
properties of drug candidates.  
One disease target for biased ligands is HIV-1 infection, an ongoing epidemic with 
approximately 2.1 million new cases worldwide in 2015. A strategy to reduce transmission of 
HIV-1 is to prevent its cellular entry (136). C-C chemokine receptor 5 (CCR5) is an obligate co-
receptor required for cellular viral entry. Cells lacking CCR5 on their surface are not susceptible 
to most strains of HIV-1 infection (137). Although endogenous chemokine agonists reduce the 
population of CCR5 on the cell surface by inducing receptor internalization, CCR5 agonists are 
not used as therapeutic agents for two reasons. First, they cause internalization of only a subset 
of CCR5, allowing HIV-1 to use receptors remaining on the cell surface for cellular entry (138). 
Second, stimulation of G proteins by activated CCR5 also promotes targeted migration of 
immune cells, leading to undesirable inflammatory side effects and enhanced HIV-1 infection at 
the site of inflammation (139, 140). In principle, a biased ligand that causes maximal receptor 
internalization, in the absence of G protein activation to avoid generating an inflammatory 
response, would be an ideal HIV-1 cellular entry blocker (141).  
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The desire for a biased, therapeutically viable HIV-1 drug that targets CCR5 has 
motivated the development of several analogs of RANTES with N-terminal modifications 
(Figure A-1A): PSC-, 6P4-, 5P12-, and 5P14-RANTES (PSC, 6P4, 5P12, and 5P14 hereafter). 
These RANTES analogs appear to show pronounced signaling bias. Optimization of AOP-
RANTES, the first potent, non-signaling chemokine analog that blocks HIV-1 entry (142), has 
generated to PSC (143). PSC behaves as a pharmacological superagonist because it appears to be 
more efficacious than RANTES at eliciting the release of intracellular Ca2+ stores and is more 
effective at causing internalization of CCR5 (141, 144). Recombinant RANTES analogs 
including 6P4, 5P12, and 5P14 have high anti-HIV-1 potency and induce CCR5 internalization. 
Like PSC, 6P4 behaves as a strong agonist that induces both Ca2+ flux and receptor 
internalization. In contrast, 5P14 does not cause Ca2+ flux signaling, but induces receptor 
internalization, suggestive of an internalization or β-arrestin-biased ligand. Finally, 5P12 binds to 
CCR5 but does not demonstrate apparent Ca2+ flux or receptor internalization (141).  
These RANTES analogs show promise in being capable of tuning the CCR5 signaling 
pathways to avoid the undesired side effect of inflammation. However, the signaling pathways 
that link CCR5 activation to its numerous physiological functions, including inflammation, 
remain poorly characterized. In addition to inducing Ca2+ flux, activation of G proteins through 
CCR5 also leads to inhibition of cAMP generation, an effect of Gi/o protein activation. However, 
it is less clear if Ca2+ flux is a result of Gq protein activation or release of Gβγ subunits following 
Gi/o protein activation in the context of CCR5 (145). 5P14, which does not trigger CCR5-
mediated Ca2+ flux, does inhibit cAMP production (146). These results suggest that CCR5-
mediated Ca2+ flux and inhibition of cAMP generation are not linked and may be mediated by 
different G proteins. Some GPCRs can signal through more than one Gα protein class depending 
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on the cellular environment and the activating ligand (147). CCR5 has been suggested to switch 
from Gi/o to Gq signaling, but the relationship between the well-established Gi/o signaling 
pathway and other G protein signaling pathways remains to be determined (148).  
Here, we tested the ability of endogenous chemokines and RANTES analogs to activate 
different Gα protein classes in the same human cell line in culture. It was important to use the 
same cell line because compositional differences of effectors between cell types can make it 
possible for a ligand to appear to be biased when different pathways are evaluated in different 
cells, a bias that is not detected if the same cell types are used for all of the assays (149). We 
measured G protein activation through several downstream pathways, including inhibition of 
cAMP generation, Ca2+ flux, and IP1 accumulation. In addition, we identified the activated Ga 
protein subtype that was responsible for these downstream events by performing assays in the 
presence of transfected individual G proteins, or in cells treated with pertussis toxin (PTX) to 
inactivate Gi/o or an inhibitor (YM-254890) to block activation of Gq (150, 151). We found that 
each of the chemokines induced Gi/o protein activation, but the chemokines varied in their ability 
to activate Gq proteins. In comparison with the endogenous chemokines RANTES (also known 
as CCL5) and MIP-1α (also known as CCL3), 6P4 and PSC acted as superagonists at Gq, 
whereas 5P12 showed no Gq activation and was Gi/o biased.  
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A.3 Methods and Materials 
A.3.1 Materials 
Coelenterazine 400A for BRET2 experiments was from Biotium. The IP-One 
homogenous time resolved fluorescence (HTRF) assay kit was from Cisbio. Forskolin, PTX and 
poly-D-lysine were from Sigma. YM-254890 was from Wako Pure Chemical Industries. 
Dulbecco’s modified Eagle’s medium Glutamax (DMEM-Q), Hank’s balanced salt-solution 
(HBSS) and Lipofectamine 2000 were from Life Technologies. Fetal bovine serum (FBS) was 
from Atlanta Biologicals. Bovine serum albumin (BSA) fraction V, fatty acid-free was from 
Roche and 96-well white, clear bottom microplate, and 384-well black, clear bottom microplates 
were from Corning. RANTES and MIP-1a were from Peprotech. The RANTES analogs 5P12, 
5P14, 6P4 and PSC were a gift from Prof. Oliver Hartley (Université de Genève).  
A.3.2 Transfection constructs 
The human CCR5 cDNA in pcDNA3.1(+) encoded a C-terminal 1D4 epitope tag 
(TETSQVAPA). The EPAC2 reporter was a gift from Prof. Michel Bouvier (Université de 
Montréal).  Gq and Gi2 α-subunit plasmids are wild-type human cDNA cloned in pcDNA3.1(+) 
(cDNA Resource Center). Gqi5 refers to a construct in which the α-subunit of Gq is modified so 
that its C-terminal tail amino acids residues are derived from the α-subunit of Gi2 (such that 
EYNLV-COOH in Gq becomes to DCGLF-COOH in Gqi5). Gqi5 was cloned into pcDNA1 
(Addgene) (152).  
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A.3.3 Cell culture and transfection 
HEK293T cells were maintained in DMEM-Q with 10% FBS. Transient transfections 
were performed using Lipofectamine 2000 according to the manufacturer’s instructions with 
some modifications as previously described (104). Cells were transfected in different plate 
formats with the following amounts of total DNA: 2 µg per well in 6-well plates; 100 ng per well 
in 96-well plates and 20 ng per well in 384-well plates. Total transfected plasmid DNA was kept 
constant by adding empty vector pcDNA3.1(+) when necessary. 
A.3.4 Adenylyl cyclase activity assay 
Inhibition of forskolin-stimulated cAMP production in response to each chemokine was 
monitored in HEK293T cells cotransfected with CCR5 and an EPAC reporter protein that shows 
a decrease in BRET upon cAMP binding (84). For each well of a 96-well plate, HEK293T cells 
(100,000 in 0.1 mL DMEM) were transfected with 12 ng RLuc3-EPAC-GFP, a BRET2 cAMP 
sensor, with or without cotransfection of 24 ng CCR5 wt. Cells were then plated at 100 µL/well 
into 96-well white, clear bottom microplates previously coated with 0.01% (w/v) poly-D-Lysine. 
Twenty-four hours post-transfection, medium was replaced with BRET buffer [phosphate buffer 
saline (PBS) containing 0.5mM MgCl2 and 0.1% BSA]. Coelenterazine 400A was added to a 
final concentration of 5 µM followed by a 5 min incubation at room temperature. Cells were then 
stimulated with chemokine in the presence or absence of 5 µM of forskolin at RT for 5 min prior 
to BRET2 reading to yield dose-response curves. Luminescence and fluorescence readings were 
collected using the Synergy NEO2 plate reader (BioTek) and Gen5 software. BRET2 readings 
117 
between RLuc3 and GFP10 were collected by sequential integration of the signals detected in the 
365- to 435- nm (RLuc3) and 505- to 525- nm (GFP10) windows. BRET2 ratios were calculated 
as previously described previously (84) and are shown as a percentage of the forskolin-
stimulated response. For experiments involving PTX, cells were treated with 100 ng/mL PTX for 
16 hours at 37°C and 5% CO2 before stimulation with forskolin and chemokines. All 
experimental manipulations were performed while cells remained attached to the 96-well plates. 
A.3.5 Ca2+ flux assay 
Ca2+ mobilization was monitored by loading CCR5-transfected HEK293T cells with a 
Ca2+-sensitive fluorescent dye and measuring changes in cytosolic Ca2+ concentrations 
immediately following chemokine addition. For each well of a 384-well plate, HEK293T cells 
(20,000 in 0.02 mL DMEM) were transfected with 10 ng CCR5 or 20 ng of empty vector. Where 
applicable, 5 ng of Gq, Gi2, or Gqi5 vector constructs were cotransfected. Cells were then plated at 
20 µL/well into 384-well black clear bottom microplates previously coated with 0.01% (w/v) 
poly-D-lysine hydrobromide. Twenty-four hours post-transfection 20 µL/well FLIPR Ca2+ 6 dye 
(Molecular Devices) was added to the cells and incubated for 1.5 hours at 37°C with 5% CO2. 
The dye was dissolved in HBSS-H (HBSS with 20 mM HEPES, pH 7.4) with 0.4% BSA. Prior 
to measurement, the plate was incubated at 37°C for an additional 30 mins in a pre-warmed 
FlexStation II 384 Plate Reader (Molecular Devices). Chemokine at a 5x final concentration was 
diluted in HBSS-H with 0.2% BSA. Fluorescence readings were collected using the FlexStation 
plate reader with excitation at 485 nm, emission at 535 nm and the dichroic mirror at 525 nm. 
The FlexStation took measurements over a 100 second time course, with 10 µL of ligand added 
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to the cells 20 seconds after the start of measurement. Relative fluorescence units (RFU) are 
reported as the peak magnitude signal minus the basal signal in each well. For experiments 
involving PTX, cells were treated with 100 ng/mL PTX for 16 hours at 37°C and 5% CO2 before 
chemokine stimulation. For experiments involving YM-254890, 10 µM of YM-254890 
(dissolved as a 10 mM stock in DMSO) or equivalent DMSO vehicle was added to the cells and 
incubated for 30 min at 37°C. 
A.3.6 IP1 accumulation assay 
IP1 concentrations in CCR5-transfected cells was measured using a competitive HTRF 
assay following incubation with each chemokine for three hours. For each well of a low-volume, 
384-well plate, HEK293T cells (5,000 in 7 µL DMEM) were transfected with 11 ng CCR5 
vector or 11 ng of empty vector. Where applicable, 5.5 ng of Gq, Gi2, or Gqi5 vector constructs 
were cotransfected. Twenty-four hours post-transfection, cells were stimulated by chemokine 
diluted in 7 µL 1X Stimulation Buffer (HEPES 10 mM, CaCl2 1 mM, MgCl2 0.5 mM, KCl 4.2 
mM, NaCl 146 mM, glucose 5.5 mM, LiCl 50 mM, pH 7.4) with 0.2% BSA and 50 mM of LiCl 
(to prevent IP1 degradation). The chemokine was incubated at 37°C for 3 hours. Following 
incubation, cells were lysed by addition of 3 μL/well of d2-fluorophore-labeled, IP1 analog as 
the fluorescence acceptor and the Terbium cryptate-labeled, anti-IP1 mAb, as the fluorescence 
donor. Both fluorescent donor and acceptor were diluted in the kit-supplied lysis buffer. The 
plates were incubated overnight at 4°C, and time-resolved fluorescence signals were read using 
the BioTek Synergy NEO plate reader (BioTek) at 620 nm and 655 nm. Results were calculated 
as a 665 nm/620 nm signal ratio, and IP1 concentrations were interpolated from a standard curve 
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prepared using the supplied IP1 calibrator. Results are shown as pmoles of IP1 formed/well. For 
experiments involving PTX, cells were treated with 100 ng/mL PTX for 16 hours at 37°C and 
5% CO2 before stimulation. For experiments involving YM-254890, 10 µM of YM-254890 or 
equivalent DMSO vehicle was added to the cells and incubated for at 37°C for 30 min.   
A.3.7 Data analysis 
Data were graphed and analyzed using GraphPad Prism 6.0 software. Dose-response curves were 
fit by a three-parameter logistic equation.  
A.4 Results 
A.4.1 RANTES analogs induce CCR5-mediated inhibition of cAMP production which depends 
on Gi/o protein activation 
We first measured the ability of the RANTES analogs to induce Gi/o activation, which is 
the canonical signaling pathway of CCR5. Gi/o activation leads to the inhibition of adenylyl 
cyclase and a decrease in the amount of cellular cAMP. We tested the ligand-dependent 
inhibition of forskolin-stimulated cAMP production in cells transfected with CCR5 vector. Each 
ligand displayed a robust dose-dependent increase in inhibition of cAMP production (Figure A-
1B). The EC50 values for inhibition of forskolin-stimulated cAMP accumulation determined for 
the ligands were all within 20-fold of each other, whereas the Emax values were within 
approximately a two-fold range (Table A-1). At the highest concentration of ligand used (100 
nM), we found that the range of Emax values was 14 to 31% inhibition of the forskolin response. 
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The rank order of maximum signal was 5P14 > RANTES > MIP-1α = 6P4 = 5P12 > PSC. The 
EC50 values of ligands ranged from 0.1 to 2.1 nM with the following rank order: 6P4 > 5P14 
>RANTES = PSC > MIP-1α = 5P12.  
Figure A-1. CCR5-mediated Gi/o protein activation by endogenous chemokines and RANTES 
analogs. (A) The RANTES analogs used in this study have modifications to the N-terminal tail 
region as shown, where p represents pyroglutamate, a represents N-nonanoyl, β represents L-
thioproline and γ represents L-2-cyclohexylglycine. (B) HEK293T cells cotransfected with 
CCR5 and the EPAC reporter plasmid were stimulated with forskolin and incubated with the 
chemokines RANTES (red, circle), MIP-1α (black, square), 5P12 (blue, diamond), 5P14 (green, 
hexagon), 6P4 (yellow, triangle) and PSC (purple, star). (C) Transfected cells were pretreated 
with 100 ng/mL of PTX (squares) or control buffer (circles) for 16 hours, stimulated with 
forskolin, and incubated with 100 nM of chemokines. Data are expressed as a percentage of 
forskolin-stimulated response and are presented as the mean ± SEM for N ³ 3 three independent 
experiments performed in at least technical triplicate. Shown are the statistical significance of the 
differences between PTX-treated and control condition for each chemokine: ****P <0.0001 
(multiple t-tests). Each chemokine tested significantly inhibited cAMP generation (p < 0.001). 
PSC and 6P4 showed enhanced inhibition of forskolin-induced cAMP generation p < 0.05  (one-
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Table A-1. Summary of fitted curve parameters for inhibition of cAMP accumulation. EC50, 
pEC50, and Emax values with SEM are given for Figure A-1B. 
RANTES MIP-1α 5P12 5P14 6P4 PSC 
CCR5 
EC50 (nM) 0.7 1 2.1 0.4 0.1 0.4 
pEC50 ± SEM -9.2 ± 0.19 -9.0 ± 0.26 -8.7 ± 0.38 -9.4 ± 0.22 -9.9 ± 0.31 -9.4 ± 0.56 
Emax ± SEM 26 ± 2.3 20 ± 2.5 18 ± 3.2 31 ± 3.1 20 ± 3.0 14± 3.4 
To confirm that inhibition of cAMP accumulation was due to Gi/o protein activation, we 
measured cAMP accumulation in cells pretreated with PTX to prevent Gi/o proteins from 
interacting with receptors. Similar to the results from the dose-response experiment, each 
chemokine demonstrated significant CCR5-mediated inhibition of cAMP accumulation in 
forskolin-treated cells. As expected, PTX pretreatment abrogated the ability of all ligands to 
inhibit forskolin-stimulated cAMP accumulation (Figure A-1C).  
A.4.2 RANTES analogs have different effects on CCR5-dependent Ca2+ flux 
In addition to inhibiting cAMP accumulation, CCR5 activation also leads to Ca2+ flux. 
Thus, we tested the ability of each chemokine and chemokine analog to induce CCR5-mediated 
Ca2+ flux. In contrast to inhibiting cAMP accumulation, not all of the ligands stimulated Ca2+ 
flux through CCR5 (Figure A-2A). The RANTES analogs induced varying amounts of Ca2+ flux 
with the rank order being 6P4 = PSC > RANTES > MIP-1α > 5P14 > 5P12. Thus, for Ca2+ flux, 
6P4 and PSC are superagonists that are more efficacious than the endogenous CCR5 chemokines 
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RANTES and MIP-1α, whereas 5P14 acts as a partial agonist and 5P12 does not have agonist 
activity. 
A.4.3 Ca2+ flux mediated by CCR5 is inhibited by Gi2 cotransfection and increased by Gq or 
Gqi5 cotransfection 
Because of the differences in signaling profiles of the RANTES analogs between Ca2+ 
flux and inhibition of cAMP accumulation, we next investigated the G protein family that was 
responsible for eliciting Ca2+ flux through CCR5 activation. Classically, Ca2+ flux is a result of 
Gq protein activation, but chemokine receptors can also induce Ca2+ flux through the release of 
Gβγ subunits following Gi/o protein activation (153, 154). To investigate the individual 
contributions of each Ga protein subtype to the Ca2+ flux signal, we repeated the Ca2+ flux 
experiments in cells in which CCR5 was cotransfected with Gq, Gi2 or Gqi5 protein. Gqi5 is an 
engineered Gq protein containing the last five amino acid residues of Gi2, which allows Gi/o-
coupled GPCRs to signal through Gq downstream signaling pathways (152).  
Cotransfection of Gi2 with CCR5 markedly inhibited the ability of RANTES and MIP-1α 
to induce Ca2+ flux through CCR5 (Fig A-2B). Gi2 cotransfection also dampened the maximum 
Ca2+ flux signal elicited in response to PSC. In contrast, cotransfection of CCR5 and Gq 
enhanced the maximal Ca2+ flux signal for all ligands, except 5P12 (Figure A-2C). In cells 
cotransfected with CCR5 and a promiscuous G protein construct, Gqi5, each RANTES analog 
induced robust Ca2+ flux (Figure A-2D), confirming the ability of all the RANTES analogs to 
activate Gi/o through CCR5.  
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Due to differences in the binding kinetics of ligands, measurements of ligand bias are 
sensitive to the experimental time scale (155, 156) . For example, Ca2+ flux assays measure a 
transient signal that is complete in two minutes, whereas cAMP accumulation is measured over 
durations of 15 minutes or more. To accurately compare the ability of each chemokine to activate 
CCR5-mediated Ca2+ flux and inhibition of cAMP accumulation, it was necessary to measure 
Ca2+ flux with an accumulation assay. Inositol triphosphate (IP3) is a product upstream of Ca2+ 
flux, and a degradation product of IP3 can be measured by an accumulation assay. Although IP3 
is rapidly degraded, its degradation product, inositol monophosphate (IP1), is stabilized by the 
addition of lithium chloride, allowing it to accumulate in the cell after receptor stimulation. In 
CCR5-expressing cells, we observed IP1 accumulation in response to only PSC (Figure A-2E), 
demonstrating that PSC functions as a superagonist as measured by IP1 accumulation and Ca2+ 
flux.  
Cotransfection of Gi2 with CCR5 reduced IP1 accumulation in response to PSC (Figure 
A-2F). In contrast, Gq cotransfection with CCR5 enhanced IP1 accumulation in response to each 
of the chemokines, except 5P12 (Figure A-2G). Moreover, Gq cotransfection with CCR5 
revealed agonist activity as measured by IP1 accumulation in response to 6P4, RANTES, MIP-
1α, and 5P14, an effect not seen in cells transfected with only CCR5. In addition, the rank order 
of maximal IP1 accumulation signal amongst the RANTES analogs was similar to that shown for 
Ca2+ flux, with 6P4 = PSC > RANTES > 5P14 > 5P12. Moreover, each of the RANTES analogs 
showed robust IP1 accumulation in cells cotransfected with Gqi5, confirming that each ligand 
activates Gi/o (Figure A-2H).  
 Together, our IP1 accumulation and Ca2+ flux data show that PSC and 6P4 are 
superagonists, whereas 5P12 lacks agonist activity in these assays. Furthermore, Gi2 
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cotransfection disrupts the ability of both endogenous CCR5 chemokines and RANTES analogs 
to induce Ca2+ flux and IP1 accumulation, whereas Gq cotransfection has the opposite effect. 
Figure A-2. The effects of G protein-subtype cotransfection on CCR5-mediated Ca2+ flux and 
IP1 accumulation in response to endogenous chemokines and RANTES analogs. Ca2+ flux in 
HEK293T cells transfected with (A) CCR5 alone or with G protein a subunits (B) Gi2, (C) Gq or 
(D) Gqi5 was measured in response to 100 nM chemokine. Fluorescence data (maximal minus 
basal) are presented as mean relative fluorescence units (RFU) ± SEM for N=4 independent 
experiments performed in technical duplicate. IP1 accumulation in HEK293T cells transfected 
with (E) CCR5 alone or with G protein a subunits (F) Gi2, (G) Gq or (H) Gqi5 was measured in 
response to 100 nM chemokine. Data are expressed as pmoles IP1 formed per well and are 
presented as mean ± SEM for N = 4 independent experiments performed in technical duplicate. 
Shown are the statistical significance of the differences between chemokine treatment and buffer 
control, and between chemokine treatment and RANTES treatment: *P<0.05, **P<0.01, ***P 
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A.4.4 CCR5-mediated Ca2+ flux is reduced by inhibiting Gi/o protein activation and abolished 
by inhibiting Gq protein activation 
 
To further differentiate between the contribution of Gi/o and Gq proteins to CCR5-
mediated signaling, we treated cells with Ga subtype-specific inhibitors. PTX prevents Gi/o 
protein coupling to GPCRs by catalyzing the ADP-ribosylation of a Cys-residue in the C-
terminal tail of Gi/o alpha subunits (157). YM-254890 prevents Gq activation by acting as a 
guanine-nucleotide dissociation inhibitor of Gq  (158). Both PTX and YM-254890 decreased 
CCR5-mediated Ca2+ flux (Figure A-3, A to D). However, YM-254890 abolished CCR5-
mediated Ca2+ flux stimulated by all chemokines, while the effects of PTX was less pronounced. 
In CCR5-expressing cells, PTX reduced Ca2+ flux induced by the superagonists 6P4 and PSC 
and completely inhibited that induced by RANTES and MIP-1α (Figure A-3A). In cells 
cotransfected with CCR5 and Gi2, both PTX and YM-254890 decreased the remaining signal 
from PSC and 6P4 (Figure A-3B). However, in cells cotransfected with CCR5 and Gq, RANTES, 
MIP-1α, and 5P14 triggered a partially PTX-insensitive Ca2+ flux response (Figure A-3C). 6P4 
and PSC also showed more PTX-insensitivity in cells cotransfected with Gq and CCR5 than in 
cells expressing CCR5 alone. Finally, the signal elicited by chemokines in cells cotransfected 
with CCR5 and the Gqi5 chimera was reduced as a result of PTX treatment, except for that 
triggered by 5P12 (Figure A-3D). Overall, in contrast to PTX, disruption of Gq activation by 
YM-254890 abolished Ca2+ signaling by each ligand even when Gq or Gqi5 were cotransfected.  
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Figure A-3. The effects of PTX and YM-254890 treatment on CCR5-mediated Ca2+ flux in 
response to endogenous chemokines and RANTES analogs. Ca2+ flux in HEK293T cells 
transfected with (A) CCR5 alone or with G protein a subunits (B) Gi2, (C) Gq, or (D) Gqi5 was 
measured in response to 100 nM of chemokine. Cells were pretreated with buffer (white bars), 
100 ng/mL PTX (gray bars), or 1 μM YM-254890 (black bars). Fluorescence data (maximal 
minus basal) are presented as mean relative fluorescence units (RFU) ± SEM for N = 4 
independent experiments performed in technical duplicate. Shown are the statistical significance 
of the differences between buffer control, PTX and YM-254890: *P<0.05, **P<0.01, ***P 
<0.001, ****P <0.0001 (two-way ANOVA, Tukey’s multiple comparison’s test).









































































A.4.5 CCR5-mediated IP1 accumulation is reduced by inhibiting Gi/o protein activation and 
abolished by inhibiting Gq  
Consistent with the Ca2+ flux experiments, YM-254890 prevented all of the chemokines 
from causing IP1 accumulation, regardless of the Ga protein subunit cotransfected (Figure A-4, 
A to D). In cells transfected with CCR5 alone, the PSC-induced IP1 signal was attenuated by 
PTX (Figure A-4A). PTX treatment of cells cotransfected with CCR5 and Gq only minimally 
reduced the IP1 signal induced by RANTES, MIP-1α, 6P4 and PSC, but had a greater effect on 
that induced by 5P14 (Figure A-4C). As with Ca2+ flux, PTX did not strongly reduce the signal 
elicited by the RANTES analogs when CCR5 was cotransfected with Gqi5 (Figure A-4D). In 
summary, although PTX caused a modest decrease in chemokine responses, YM-254890 
abolished the ability of each of the ligands tested to elicit IP1 accumulation and Ca2+ flux. Thus, 
both cotransfection and inhibition experiments suggest that Gq is the dominant G protein in 
stimulating Ca2+ flux following CCR5 activation, with Gi/o playing a much smaller role.  
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Figure A-4. The effects of PTX and YM-254890 treatment on CCR5-mediated IP1 
accumulation in response to endogenous chemokines and RANTES analogs. IP1 accumulation in 
HEK293T cells transfected with (A) CCR5 alone or with G protein α subunits (B) Gi2, (C) Gq, or 
(D) Gqi5 was measured in response to 100 nM of chemokine. Cells were pretreated with buffer 
(white bars), 100 ng/mL PTX (gray bars), or 1 μM YM-254890 (black bars). Data are expressed 
as pmoles IP1 formed per well and are presented as mean ± SEM for N = 4 independent 
experiments performed in technical duplicate. Shown are the statistical significances of the 
differences between buffer control, PTX and YM-254890: *P<0.05, **P<0.01, ***P <0.001, 


























































A.4.6 Cotransfection of CCR5 with Gi/o, Gq or Gqi5 causes different effects on Emax values and 
EC50 values 
The effects of G protein cotransfection with CCR5 could be a result of a change in ligand 
Emax (maximum signal) or EC50 (the concentration of ligand required for half-maximal signal). 
Performing and fitting dose-response curves for Ca2+ flux (Table A-2) showed that in cells 
transfected with CCR5, EC50 values ranged from 21.0 nM to 240 nM with the rank order of PSC 
= 6P4 = RANTES = 5P14 > MIP-1α (Figure A-5A). Emax values ranged from 2700 to 45000 
RFU and the rank order was 6P4 > PSC > RANTES = MIP-1α > 5P14. Cotransfection of CCR5 
and Gi2 decreased Ca2+ flux such that only PSC and 6P4 could elicit any measurable Ca2+ flux 
response (Figure A-5B), which was due to reduced Emax values because EC50 values in cells 
transfected with CCR5 were similar to those in cells cotransfected with both CCR5 and Gi2. 
Similarly, the increase in response from each chemokine in cells cotransfected with CCR5 and 
Gq was not a result of altered EC50 values, but rather due to an increase in Emax values (Figure A-
5C). In contrast to Gi2 and Gq, cotransfection of Gqi5 and CCR5 altered both EC50 and Emax values 
in dose-response Ca2+ flux experiments (Figure A-5D). The range of EC50 values amongst the 
ligands tested decreased, but the rank order was similar, with 6P4 = RANTES > PSC > 5P14 = 
MIP-1α > 5P12. In addition, the Emax value of each ligand increased, but the rank order also 
remained the same. 
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In cells transfected with CCR5 alone, only PSC showed any dose-dependent IP1 
accumulation, with an EC50 of 190 nM (Figure A-5E) (Table A-3). No agonist-stimulated IP1 
accumulation was observed in cells cotransfected with CCR5 and Gi2 (Figure A-5F).  Cells 
cotransfected with CCR5 and Gq displayed a range of EC50 values for IP1 accumulation of 4.3 
nM to 72 nM with a rank order of 5P14 > 6P4 > RANTES = PSC. Theses EC50 values were 
similar to those for Ca2+ flux (Figure A-5C and G).  The Emax values ranged from 1.0 to 8.4 
pmoles/well with rank order of PSC > 6P4 > 5P14 > RANTES, although the curve fits for 5P12 
and MIP-1a were ambiguous. This rank order of Emax values was similar to that observed with 
Ca2+ flux in CCR5-transfected cells both with and without cotransfection of Gq. As seen 
previously, cotransfection of Gqi5 and CCR5 allowed each RANTES analog to cause IP1 
accumulation (Figure A-5H). This increase in signal caused by Gqi5 cotransfection with CCR5 
could be attributed to a decrease in EC50 values for all ligands tested. In addition, an increase in 
Emax contributed to the higher signals for RANTES, MIP-1α, 5P12, and 5P14 in cells 
cotransfected with Gqi5 and CCR5. 
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Figure A-5. Dose-response curves for CCR5-mediated Ca2+ flux and IP1 accumulation. Ca2+ 
flux in HEK293T cells transfected with (A) CCR5 alone or with G protein a subunits (B) Gi2, 
(C) Gq, or (D) Gqi5 was measured in response to RANTES (red, circle), MIP-1α (black, square), 
5P12 (blue, diamond), 5P14 (green, hexagon), 6P4 (yellow, triangle) and PSC (purple, star). 
Fluorescence data (maximal minus basal) are presented as mean relative fluorescence units 
(RFU) ± SEM for N = 4 independent experiments performed in technical triplicate. IP1 
accumulation in HEK293T cells transfected with (E) CCR5 alone or with G protein a subunits 
(F) Gi2, (G) Gq, or (H) Gqi5 was measured in response to RANTES (red, circle), MIP-1α (black, 
square), 5P12 (blue, diamond), 5P14 (green, hexagon), 6P4 (yellow, triangle) and PSC (purple, 
star). Data are expressed as pmoles IP1 formed per well and are presented as mean ± SEM for 

































































































Table A-2. Summary of fitted curve parameters for Ca2+ flux. EC50, pEC50, and Emax values with 
SEM are given for Figure A-5, left column. ND, not detectable 
RANTES MIP-1α 5P12 5P14 6P4 PSC 
CCR5 
EC50 (nM) 32 240 ND 21 36 25 
pEC50 ± SEM -7.6 ± 0.2 -6.5 ± 0.2 ND -7.7 ± 0.7 -7.4 ± 0.1 -7.6 ± 0.1 
Emax ± SEM 12000 ± 1000 15000 ± 2000 ND 3000 ± 1000 45000 ± 2000 31000 ± 2000 
CCR5 + Gi2 
EC50 (nM) ND ND ND ND 110 42 
pEC50 ± SEM ND ND ND ND -6.9 ± 0.3 -7.4 ± 0.3 
Emax ± SEM ND ND ND ND 15000 ± 3000  10000 ± 2000 
CCR5 + Gq 
EC50 (nM) 32 460 ND ND 21 26 
pEC50 ± SEM -7.5 ± 0.1 -6.3 ± 0.3 ND ND -7.7 ± 0.1 -7.6 ± 0.1 
Emax ± SEM 20000 ± 2000 27000 ± 8000 ND ND 61000 ± 4000 64000 ± 2000 
CCR5 + Gqi5 
EC50 (nM) 0.9 5.1 23 3.6 0.7 1.8 
pEC50 ± SEM -9.0 ± 0.1 -8.3 ± 0.1 -7.6 ± 0.1 -8.4 ± 0.1 -9.1 ± 0.1 -8.7 ± 0.1 
Emax ± SEM 50000 ± 4000 50000 ± 3000 19000 ± 1000 45000 ± 2000 77000 ± 4000 67000 ± 3000 
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Table A-3. Summary of fitted curve parameters for IP1 accumulation. EC50, pEC50, and Emax 
values are given for Figure A-5, right column. ND, not detectable 
RANTES MIP-1α 5P12 5P14 6P4 PSC 
CCR5 
EC50 (nM) ND ND ND ND ND 190 
pEC50 ± SEM ND ND ND ND ND -6.7 ± 0.4 
Emax ± SEM ND ND ND ND ND 1.7 ± 0.3 
CCR5 + Gi2 
EC50 (nM) ND ND ND ND ND ND 
pEC50 ± SEM ND ND ND ND ND ND 
Emax ± SEM ND ND ND ND ND ND 
CCR5 + Gq 
EC50 (nM) 65 ND ND 4.3 18 72 
pEC50 ± SEM -7.2 ± 0.4 ND ND -8.3 ± 0.3 -7.7 ± 0.1 -7.1 ± 0.1 
Emax ± SEM 1.0 ± 0.2 ND ND 1.6 ± 0.3 7.4 ± 0.1 8.4 ± 0.1 
CCR5 + Gqi5 
EC50 (nM) 6 2.9 0.5 0.6 3.5 25 
pEC50 ± SEM -8.2 ± 0.1 -8.5 ± 0.1 -9.3 ± 0.4 -9.2 ± 0.2 -8.5 ± 0.1 -7.6 ± 0.1 
Emax ± SEM 3.1 ± 0.3 3.0 ± 0.2 2.3 ± 0.4 5.3 ± 0.4 5.8 ± 0.5 5.4 ± 0.3 
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In summary, Emax values were altered when Gi/o or Gq were cotransfected with CCR5, 
while both Emax and EC50 values were altered when Gqi5 was cotransfected with CCR5.  These 
results show that when CCR5 is cotransfected with either Gi2 or Gq, the Emax values, but not the 
EC50 values, for agonist-dependent IP1 accumulation and Ca2+ flux were altered. In contrast, 
cotransfection of CCR5 and Gqi5 caused a decrease in EC50 values for IP1 accumulation and Ca2+ 
flux for all ligands tested. In addition, coexpression of CCR5 and Gqi5 led to an increase in Emax 
values for Ca2+ flux for all ligands, and an increase in Emax values for IP1 accumulation for most 
ligands tested. 
A.5 Discussion 
Several GPCR-targeted ligands have been described to cause signaling bias toward β-
arrestin or G protein signaling pathways. However, reports of ligands that bias GPCR signaling 
towards a specific Gα protein class are rare, in part because of the difficulty in interpreting 
signaling assays in which crosstalk between different G protein signaling pathways occurs. In 
this study, we determined the specific Gα protein class that was responsible for CCR5-mediated 
inhibition of cAMP accumulation, Ca2+ flux, and IP3 production. Analogs of the endogenous 
chemokine RANTES with N-terminal modifications showed similar abilities to activate CCR5-
mediated Gi/o signaling, but either enhanced or decreased abilities to activate CCR5-mediated Gq 
signaling. 
For inhibition of cAMP accumulation, each of the endogenous chemokines and the 
RANTES analogs tested acted as agonists with similar Emax values and EC50 values of 2.1 nM or 
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lower. EC50 values at least one order of magnitude higher were obtained earlier from CCR5-
transfected CHO cells, which also showed a lack of detectable signal for 5P12 (146). In addition 
to the use of different cells, the source of variation between these results could be due to the use 
of different ligand incubation times or different assays to detect cAMP (real-time changes of 
cAMP in live cells compared with measurement of cAMP after a single incubation time point) 
(146). 
The RANTES analogs showed different abilities to induce Ca2+ flux and IP1 
accumulation through CCR5. In comparison to the endogenous chemokines RANTES and MIP-
1α, the RANTES analogs 6P4 and PSC acted as superagonists, while 5P12 did not have agonist 
activity in the Ca2+ flux assays. Our measurements of EC50 and Emax values recapitulated the 
results from Ca2+ flux assays performed in CCR5-transfected Hela-P5L and PHA/IL-2-activated 
T blasts (141). Cells expressing only CCR5 demonstrated IP1 accumulation in response only to 
PSC whereas CCR5-mediated Ca2+ flux was measured in response to RANTES, MIP-1α, 6P4, 
and PSC. The differences between results when assessing Ca2+ flux and IP1 accumulation is 
likely due to assay sensitivity (159). Of note, the ability of the RANTES analogs to induce 
CCR5-mediated Gq signaling appears to correlate with their ability to induce β-arrestin 
recruitment and internalization. Analogous to the Ca2+ flux results, only 5P12 was unable to 
induce CCR5-internalization and β-arrestin recruitment to CCR5 (160). In addition, cells treated 
with PSC demonstrated the strongest recruitment of β-arrestin to CCR5, followed by RANTES, 
and then 5P14 (146, 161, 162). 
The differences in the signaling profiles of the RANTES analogs suggests that different 
effectors are responsible for CCR5-mediated inhibition of cAMP accumulation or induction of 
Ca2+ flux. Gi/o protein activation inhibits cAMP accumulation, a pathway further confirmed by 
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our results. 6P4 and PSC can stimulate cAMP production above levels induced by forskolin in 
the presence of PTX, suggesting that these ligands might also stimulate CCR5-mediated Gs 
protein activation. The differential regulation of adenylated cyclase subtypes in HEK293 cells 
could also be the source of this PTX-dependent cAMP production by 6P4 and PSC. Ca2+ can 
activate certain subtypes of adenylate cyclase, causing crosstalk between Ca2+ signaling and 
cAMP production (163). Alternatively, 6P4 and PSC in presence of PTX could inhibit the 
degradation of forskolin-dependent cAMP, and these ligands would not induce cAMP production 
in the presence of PTX, but the absence of forskolin. 
The Gα protein subunit that is responsible for Ca2+ flux and IP3 formation is less clear 
but could be Gq or Gi/o. Cotransfection of Gq augments CCR5-mediated Ca2+ flux and IP1 
accumulation, responses that are inhibited by cotransfection of Gi2, which supports the 
hypothesis that Gq is responsible for Ca2+ flux. Gi2 transfection could inhibit Ca2+ flux and IP1 
accumulation through CCR5 by either preventing Gq recruitment by competitively binding to 
CCR5, or by acting as a Gβγ subunit scavenger, which would prevent the formation of 
heterotrimeric Gq proteins required for G protein activity.  
We further differentiated the contributions of Gi/o and Gq proteins to CCR5-mediated Ca2+ 
flux and IP3 signaling using inhibitors. The Gq inhibitor YM-254890 prevented all of the 
RANTES analogs from inducing CCR5-mediated Ca2+ flux and IP1 accumulation. However, the 
ability of PTX to at least partially inhibit Ca2+ flux and IP1 accumulation does not support the 
hypothesis that Gq mediates these signaling pathways through CCR5. This seemingly 
paradoxical result can be explained by the indirect effect of PTX decreasing binding of 
chemokines to CCR5 (138). Reduction of agonist affinity is likely due to a reduction of Gi/o
protein pre-coupling to CCR5. Structural studies of b2AR interacting with G protein has 
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confirmed the paradigm that a receptor must be bound to a transducer to stabilize the agonist-
receptor interaction (164). Likewise, the conformation of CCR5 molecules on the cellular surface 
is altered upon PTX-induced abrogation of Gi/o pre-coupling (165). Similar to our results, other 
reports have also described incomplete inhibition of CCR5-mediated Ca2+ flux by PTX, 
suggesting that Gi/o plays a role in agonist binding but not in mediating Ca2+  flux (166–168). 
Finally, it is unlikely that Gβγ subunits could induce Ca2+ flux in HEK293T cells because the 
closely related HEK293 cell line does not produce the phospholipase C subunit that links Gβγ 
release to Ca2+ flux (169). Although we cannot rule out a contribution from Gβγ, our data 
suggest that Ca2+ flux signaling through CCR5 in this cellular system is mainly, if not 
completely, mediated by Gq protein activation.  
Chemokine receptors are historically believed to couple to and signal through Gi/o
proteins exclusively. The Ca2+ flux response elicited by many chemokine receptors has been 
thought to be a result of Gβγ subunit release after activation of Gi/o (153). However, we provide 
evidence that CCR5 signals through both Gi/o and Gq/11 proteins. We also demonstrate that IP1 
accumulation and Ca2+ flux are products of Gq protein signaling in HEK293T cells. CCR5 
mediates PTX-insensitive signaling responses, suggesting the CCR5 couples to and signals 
through other G proteins (148, 166, 167). Indeed, CCR5 couples to and co-immunoprecipitates 
with Gq (170, 171). Both Gq and Gi/o protein signaling may contribute to the activities of other 
chemokine receptors. CXCR4 is proposed to switch from Gi/o signaling to Gq signaling, leading 
to reduced migration and activation of the T cells (148, 172). In addition, CXCR4 and CCR7-
dependent chemotaxis of dendritic cells requires activation of both Gi/o and Gq pathways (173). 
Theoretically, the capacity of a receptor to couple to certain Gα protein subunits should be 
apparent from its primary structure. However, although residues in similar positions in different 
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GPCRs recognize G proteins, other distinct residues also make structural binding contacts. 
Therefore, without the availability of comparable structures of Gi/o and Gq bound to activated 
GPCRs, it is difficult to surmise whether Gq coupling to other chemokine receptors can be 
predicted or validated by structural information (174).  
The capacity of each chemokine to bind to different conformations of CCR5 likely 
accounts for apparent differences to induce CCR5-mediated signaling through either Gi/o- or Gq-
dependent pathways. The “spare receptor” concept posits that there are at least two pools of 
inactive CCR5: receptors pre-coupled to Gi/o proteins, and “naked” receptors not pre-coupled to 
Gi/o protein (138, 175). CCR5 can assume multiple conformations, as shown by monoclonal 
antibody detection of different populations of CCR5 (176). The endogenous chemokines 
RANTES and MIP-1α bind with high affinity to only Gi/o protein-coupled CCR5, whereas PSC 
has a high affinity for both Gi/o protein-coupled CCR5 and naked CCR5 (138). Single molecule 
binding experiments have also shown that 5P12, 5P14, PSC and 6P4 bind to CCR5 with 
affinities of 374 pM, 493 pM, 10 nM, and 6.5 nM, respectively, in the absence of G protein. 
However, MIP-1a and RANTES do not show detectable binding to naked receptor up to 
concentrations of 10 µM (177). Thus, PSC can activate a subset of CCR5 molecules that remains 
inactive after stimulation with RANTES (175). The increased Ca2+ flux in response to PSC or 
6P4 is likely due to the activation of naked CCR5, in addition to Gi/o-protein pre-coupled CCR5. 
In line with this hypothesis, PSC and 6P4 do not have substantially lower EC50 values than 
RANTES, but do have higher Emax values, suggesting that these chemokines are superagonists 
because they bind to more receptors, rather than because they bind with higher affinity. 
 We present a model to contextualize the results of our experiments and hypothesize about 
how RANTES analogs are capable of showing G protein-subtype specific signaling bias (Figure 
140 
A-6A). For RANTES and MIP-1α, Gi/o subunit pre-coupling promotes binding of the ligand to 
the receptor, upon which Gi/o is activated and dissociates from the receptor. A ligand that 
remains bound to the receptor can recruit and activate Gq or additional Gi/o proteins. In contrast 
to RANTES and MIP-1α, PSC and 6P4 can bind to and activate CCR5-dependent signaling 
pathways, independently of whether the receptor is pre-coupled to Gi/o or naked.  By signaling 
through two pools of the receptor, PSC and 6P4 can produce more signal and thus act as 
superagonists. Although not apparent from our data, 5P12 binds to CCR5 in a G-protein 
independent fashion (138) and thus, binding of 5P12 to naked CCR5 preferentially activates Gi/o
(Figure A-6B) . 
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Figure A-6. Conceptual model depicting CCR5-mediated signaling through Gi/o and Gq by 
endogenous chemokines and RANTES analogs. The CCR5 receptor exists in at least two 
populations, with a group of CCR5 molecules pre-coupled to Gi/o (grey background) and another 
group in an uncoupled, or “naked” state (blue background). (A) RANTES and MIP-1α bind only 
to Gi/o-precoupled CCR5, which then leads to activation of Gi/o. Following activation of Gi/o,
CCR5 then can recruit and activate Gq. 6P4 and PSC bind to both Gi/o-precoupled CCR5 and 
naked CCR5. Thus, activation of Gq protein occurs independently of Gi/o proteins. (B) 5P12 
binds to both Gi/o-precoupled CCR5 and naked CCR5, but binding leads to activation of Gi/o
only.  
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This study demonstrates a type of ligand bias that is G protein family specific. Another 
peptide receptor, pituitary adenylate cyclase-activating polypeptide (PACAP) receptor, responds 
to the two ligands PACAP-38 and PACAP-27 with similar EC50 values for the Gs signaling 
pathway. However, the two PACAP receptor ligands have EC50 values that are 100-fold different 
for a Gq signaling pathway (178). The free fatty acid receptors (FFAR) also signal through 
multiple G protein families, but depending on the activating ligand, the FFARs can selectively 
signal through a single G protein family. For example, synthetic agonists targeting FFAR1 can 
signal through both Gq and Gs, whereas the endogenous agonists signal only through Gq (179). In 
addition, an allosteric modulator targeting FFAR2 selectively activates Gi/o signaling but not Gq 
signaling (180). In our study, we described chemokines with similar capacity to evoke CCR5-
mediated Gi/o signaling, but with both diminished and enhanced Gq signaling.  
How the modification of the N-terminal region of RANTES leads to such pronounced 
changes in CCR5-mediated Gq signaling, but not Gi/o signaling, is unclear. Nonetheless, some 
insight can be garnered from crystal structures of CCR5, including CCR5 in complex with 5P7, 
another RANTES analog (181, 182). 5P7 differs from 5P12 by one amino acid, Thr instead of 
Leu at position 7, and lacks agonist activity for Ca2+ flux (141). When comparing the crystal 
structure of 5P7 to a model of CCR5 with RANTES, several different interactions are apparent 
that could be key for Gq protein activation. Whereas RANTES has polar residues in positions 4 
to 7 that can engage a minor pocket polar network, 5P7 has bulky hydrophobic residues at these 
positions. Similarly, the Gq-inactive RANTES analogs 5P12 and 5P14 have bulky hydrophobic 
residues at positions 4 to 7, whereas the superagonist PSC has polar residues. However, the 
superagonist 6P4 has mostly less-bulky hydrophobic amino acids at these positions. A crystal 
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structure of CCR5 engaged with a superagonist will be necessary to understand precisely how Gq
signaling is modulated by changes in the N-terminal sequences of RANTES.  
The RANTES analogs 5P12 and 5P14, which fail to activate Gq, may be safer drugs 
because they discriminate between Gi/o and Gq protein activation. In bypassing Gq signaling, 
several physiological effects of CCR5 activation that are PTX-resistant or downstream of Ca2+
flux would be avoided, including CCR5 recruitment to the immunological synapse during T cell 
stimulation (148). In addition, an in vitro predictor of an inflammatory response, chemotaxis, 
requires additional GPCR signaling because Gi/o signaling is necessary, but not sufficient, to 
induce chemotaxis (154). Because Ca2+ flux is necessary for actin rearrangement, an important 
step in chemotaxis, it is plausible that this additional signaling component is Gq activation (183). 
Although the RANTES chemokines have not been compared in their ability to induce 
chemotaxis, PSC does cause chemotaxis of CD4 T-cells (138).  The contribution of these two 
signaling arms to the physiological effects of CCR5 activation remain unknown. Thus, these 
RANTES analogs could serve as tools to determine the effects of Gi/o signaling alone compared 
with Gq and Gi/o protein signaling in combination. Future studies should utilize these chemokine 
analogs to determine how CCR5-mediated Gi/o and Gq signaling affect events such as chemotaxis 
and T cell activation using physiologically-relevant cell types.  
In conclusion, we investigated G protein subtype-specific biased signaling of the 
chemokine receptor CCR5 using a series of chemokine analogs developed as HIV-1 
microbicides. Using a specific inhibitor, we found that Gq/11 is responsible for Ca2+ flux 
downstream of CCR5 in HEK293T cells, which earlier had been attributed to Gbg subunit 
released from Gi/o. RANTES analogs had a wide range of efficacy for CCR5-mediated Gq 
signaling, but similar Gi/o signaling efficacy, opening the possibility for selectively tuning 
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chemokine signaling. Non-canonical Gq/11 signaling bias in the chemokine receptor network to 
our knowledge has not been previously reported.  Our findings also provide an experimental 
strategy in which a Gq-specific inhibitor is used to study Gq signaling bias relevant to Ca2+ flux 
signals from GPCRs thought to couple to Gi/o. 
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